Cancer.Net Podcast
ASCO
Subscribe
Cancer.Net Podcast features trusted, timely, and compassionate information for people with cancer, survivors, their families, and loved ones. Expert tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care
Available episodes
Newest first
Oldest first
Jan 26, 2023
Lymphoma Highlights from the 2022 American Society of Hematology Annual Meeting, with Christopher Flowers, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Christopher Flowers covers new research in non-Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting, held December 10-13 in New Orleans, Louisiana.
Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and was appointed Division Head ad interim of Cancer Medicine in August 2020.
View Dr. Flowers’ disclosures at Cancer.Net.
Dr. Flowers: Hello and welcome to this Cancer.Net podcast. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center. And it's my great pleasure to talk to you today about updates in lymphoma from this year's American Society of Hematology meeting in December of 2022. I have a number of disclosures related to my work as a consultant for companies in the development of therapies for lymphoma. I will not talk about agents specifically related to those companies, but 2 companies that overlap with some of the areas that I'll talk about in bispecific antibodies includes Genentech, Roche, and Genmab, as well as research support from those companies for research that is performed at MD Anderson. So this year's American Society of Hematology meeting had a number of highlights. I was very fortunate to be the introducer for one of those key highlights, and that was the abstract presented at this year's plenary session. This was actually the first abstract presented in the plenary session where I introduced the abstract and set the context, and Dr. Martin Dreyling from the German group described the TRIANGLE study. So the TRIANGLE study was a randomized controlled clinical trial, meaning that the trial was performed in a randomized fashion to be able to test 3 particular strategies for patients with mantle cell lymphoma.
Mantle cell lymphoma, as many of you may know, is a relatively uncommon form of non-Hodgkin lymphoma. It's a kind of lymphoma that can be quite aggressive, and particularly for younger patients who are suitable for aggressive therapy, the role of autologous stem cell transplantation has been something that's been important for the first-line therapy for mantle cell lymphoma. This study evaluated the use of a standard regimen of giving R-CHOP chemotherapy alternating with R-DHAP chemotherapy. So a chemotherapy regimen that includes Ara-C as their component followed by autologous stem cell transplantation. And it compared using that same regimen to giving it with ibrutinib added to the R-CHOP portion of the chemotherapy, followed by ibrutinib maintenance after the stem cell transplant or another experimental arm that added ibrutinib to the R-CHOP portion of the chemotherapy and gave 2 years of ibrutinib maintenance without stem cell transplantation. I think, importantly, this arm compared to each of those 2 experimental arms versus the standard of care and showed graphically that both of the arms that contained ibrutinib, the BTK inhibitor, looked to have improved failure-free survival compared to the standard stem cell transplant arm. Formal statistical tests were performed to compare the arm that included transplant plus ibrutinib showing that that was superior to transplant alone. And it remains to be seen whether that arm is superior to the arm that used ibrutinib alone.
But those 2 arms look fairly similar in terms of their outcomes, and also the toxicity associated with the transplant obviously was substantially more than performing the therapy without transplant. This suggested perhaps autologous stem cell transplantation can be removed from frontline therapy for patients with aggressive mantle cell lymphoma and provides provocative data that may help to change practice, both in Europe and in the United States, as well as the rest of the world.
A few other abstracts that were presented at this year's ASH meeting presented provocative data about ways to be able to improve the ways that we predict outcomes for patients. Matt Maurer presented the results of the Follicular Lymphoma International Prognostic Index 24, or the FLIPI24, as a risk factor to try and predict patients who might have early progression of disease with follicular lymphoma. One of the things that we know is that when you look at patients with follicular lymphoma, those patients who have progression of their disease within 24 months of the start of chemoimmunotherapy are patients that have markedly worse outcomes. And Dr. Maurer and our colleagues led an international study showing that a new prognostic factor model that included age, hemoglobin, white blood cell count, normalized lactate dehydrogenase, and beta-2-microglobulin, so all laboratory values that are connected within routine clinical practice, along with age, were a better predictor of this early progression of disease. This may serve as a useful model moving forward to help patients and their providers to understand who are the patients who are at higher risk of having aggressive behaving follicular lymphoma, and eventually, we can make strategies that help to address that for those patients.
A second provocative model for using integrated genomics helps to identify patients who also have early progression of disease, and those are for patients with diffuse large B-cell lymphoma. This was presented by Kirsten Wenzel from the Mayo group, where Anne Novak was the senior author for this publication. What they did was they integrated the genomics into the clinical prognostic factors and found that there was a particular RNA-seq profile that helped to identify those patients who had early progression of disease with diffuse large B-cell lymphoma. They compared this approach to other prognostic models and suggested that these approaches may be able to improve upon the prediction of outcomes and be incorporated into the ways that we predict treatment strategies for patients with diffuse large B-cell lymphoma in the future. While these are still early on in their development, I think this holds promise for the future management of patients.
And then the other class of agents that I'll mention from this year's ASH meeting are the bispecific antibodies. There were several abstracts that addressed this, both in patients with relapsing, refractory, diffuse large B-cell lymphoma, and in patient populations with relapsing refractory follicular lymphoma. One of those highlighted came from Nancy Bartlett, who discussed the role of a specific bispecific antibody for patients with relapsed follicular lymphoma. And I think these agents hold broad promise. So I appreciate your time and attention and hope you enjoyed this podcast and look forward to talking to you in the future about new developments in lymphomas broadly.
ASCO: Thank you, Dr. Flowers. You can find more research from recent scientific meetings at www.cancer.net.
Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping w…
playlist_add
Jan 5, 2023
Finding Purpose And Sharing Your Story After Cancer, with Rachael Kearney
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, esophageal cancer survivor Rachael Kearney shares her story with Dr. Frank Penedo, Associate Director of Cancer Survivorship & Behavioral Translational Sciences and the Director of the Cancer Survivorship Program at the University of Miami Sylvester Comprehensive Cancer Center, and an Advisory Panelist on the Cancer.Net Editorial Board.
They discuss her podcast, Call On Courage, which features conversations connected to courage, starting over, and overcoming. They also discuss the value in sharing your story, and tips for people with cancer and survivors.
You can view disclosures for Dr. Penedo and Ms. Kearney at Cancer.Net.
Dr. Frank Penedo: Hello, I am Frank Penedo. I am the associate director of cancer survivorship and behavioral translational sciences and also the director of cancer survivorship and supportive care programs at the University of Miami Sylvester Comprehensive Cancer Center. I'm also an advisory panelist on the Cancer.Net Editorial Board. Today, it is my pleasure to welcome and talk with Rachael Kearney. Rachael is an esophageal cancer survivor who lives in Manchester, England. After she received her cancer diagnosis, Rachael started a podcast called Call On Courage, which features conversations connected to courage, starting over, and overcoming in general. Rachael, thank you so much for talking with us today.
Rachael Kearney: Thanks for having me, Frank. I'm excited to get into this conversation.
Dr. Frank Penedo: Before we begin, Rachael, I should mention that we have no relationship to disclose related to this podcast today. Rachael, can you please tell us a little bit about your experience being diagnosed with cancer and your journey thereafter and what was it like?
Rachael Kearney: Yeah, so this is kind of coming into about 15 months ago. Out of nowhere, I had sort of severe acid reflux. And I was due to meet up with some girlfriends in Manchester, and I was just really struggling to eat my breakfast. It was just bizarre because I've not had those type of symptoms before. And essentially, what happened very quickly, within a 3-week period, this acid reflux increased, and it got worse. And it got to the point where I couldn't tolerate water. So I knew something was seriously up. But there was a waiting period before I got admitted to hospital, before I could have an endoscopy, which is obviously what I knew was going to get to the bottom of things to find out what was going on. And, yeah, it was just very scary in terms of not being able to tolerate normal food. But essentially, when I did get admitted, the endoscopy appointment came a lot quicker within a matter of 2 days, and then the actual diagnosis of esophagus cancer was within 24 hours after that. Obviously, it was just a massive shock because there wasn't a history of this in my family. And at the time, I was only 42. I'm 43 now. And it just felt very bizarre because I hadn't heard of anyone else that had esophagus cancer in my age group or friendship circles or whatever.
Dr. Frank Penedo: Yeah, you mentioned, Rachael, a couple of words in there that stand out. It's just a shock of that diagnosis and, of course, the fear that comes along with that. It sounds like you were able to get proper attention pretty quickly, which is obviously very important when dealing with a cancer diagnosis. But can you tell us a little bit about how you dealt with that initial shock and fear?
Rachael Kearney: So the weird thing was I was in shock, but I wasn't scared. And I don't know why, logically. I don't know why I wasn't struggling with a lot of anxiety. I don't know. There was just this inner sense, that things were going to get treated quite quickly. And, I mean, I had 2 surgeons because-- I don't know what the procedure is like in other countries, but in the UK, the treatment plan was a sandwich of chemotherapy and esophagectomy, and then chemotherapy at the end of that. The esophagectomy is the critical bit because the surgery essentially-- mine was actually an advanced tumor, so it had been there a while. So I knew surgery was the best course of action because this thing had been growing inside of me. And it was like-- it's a drastic surgery, the esophagectomy, because they're obviously removing a chunk of your esophagus, and you're also having essentially a gastric band. I was massively into fitness before I had cancer, so it almost sounds slightly annoying now, but the challenge now is more to focus on getting the calories in. And maintaining good weight is the focus. But that said, I think it was just a lot of-- I was having to process a lot of information because the treatment was coming at me quite quickly. And there was things about it lifestyle-wise that-- because prior to chemotherapy, I was on a feeding tube to get my nutrition. And at the time, I was more concerned that I wouldn't be able to eat in the normal way, that I'd maybe end up long-term on a feeding tube, which was something that was-- you've got all these questions about what your future and your lifestyle looks like post-esophagus cancer, and that was kind of in the mix.
But I think one of the things that was amazing was I had a lot of community, I had a lot of support around me in Manchester. So I was really fortunate, even though there were some wards within the local hospital I was in that were COVID-restricted still in terms of visitors, they made allowance for me to be able to have visitors and stuff like that. So I was really fortunate and even had a friend that worked in the hospital that would come and see me at the end of her shifts and stuff like that. So I had a lot of people checking in when I was in hospital, so I felt very supported through that process. But the thing that's complicated is you're very unwell and you're having to take in lots of information in terms of your treatment plan. And then they can't give you guaranteed scenarios of what your lifestyle is going to look like at the end of surgery. So that's the grey area, really. Yeah.
Dr. Frank Penedo: Sure, Rachael. And cancer in itself, it can be very challenging, let alone during a pandemic, when we have to adjust so many other aspects of our life. But it sounds like you had a pretty good support system, which, as we know, helps our cancer patients and survivors really manage the experience and get through. You touched a little bit upon your treatment. You mentioned it included surgery and reshaping of your esophagus and the stomach. And you touch upon the effects of surgery, which can be persistent. It can really persist well beyond that active treatment period. Can you talk a little bit more about how you've been able to cope with these side effects and changes that you've experienced?
Rachael Kearney: Yeah, so I was a massive foodie before all of this, very food-orientated. Food was almost, in family and friendship circles, a love language. And Manchester's got a thriving food scene out in the city and stuff, so a lot of socializing revolved around food. And I think the great thing about the upper GI ward that I was on at the time is there's no secrets and there's no sugar coating everything. They give you probably sometimes…
playlist_add
Dec 20, 2022
What Do Health Equity and Quality Care Mean for Cancer Care?
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net Podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clinical Oncology. Today, we're going to be talking about what health equity and quality care mean in the context of cancer care and discuss highlights from the 2022 Quality Care Symposium in these areas. Our guests today are Dr. Fay Hlubocky and Dr. Manali Patel. Dr. Hlubocky is a licensed clinical health psychologist with an expertise in psychosocial oncology and a health care ethicist at the University of Chicago. She's also the Cancer.Net Associate Editor for Psychosocial Oncology. Thanks for joining us today, Dr. Hlubocky.
Dr. Fay Hlubocky: Thank you, Brielle. Hello, everyone. So wonderful to be with you all today.
Brielle Gregory Collins: Thank you so much. And Dr. Patel is an assistant professor at Stanford University in the division of oncology and a staff thoracic oncologist at the Veterans Affairs Palo Alto Health Care System. She's also the Cancer.Net Associate Editor for Health Equity. Thanks for joining us today, Dr. Patel.
Dr. Manali Patel: Of course. And thanks for hosting both me and Fay to discuss this really fun topic.
Brielle Gregory Collins: Of course, we're looking forward to it. Before we begin, we should mention that Dr. Hlubocky and Dr. Patel do not have any relationships to disclose related to this podcast, but you can find their full disclosure statements on Cancer.Net. So to start, Dr. Patel, can you first describe what the term health equity means and how it relates to cancer care?
Dr. Patel: Great question. Nice one to start off this podcast. So I think we've always been really focused on health disparities. So I love that you've asked, what is health equity? Health equity is really reframing disparities or differences in cancer outcomes with more of a justice lens. And the full definition, which I love from the Robert Wood Johnson Foundation, describes health equity as meaning that everyone has a fair and just opportunity to be as healthy as possible. This means that you remove obstacles that may impede people's ability to attain their highest health, such as poverty, discrimination, and the consequences of such powerlessness, lack of access to good jobs, having fair pay, quality education and housing, safe environments, and health care. And as it relates to cancer care, it means that everyone has a fair and just opportunity to be as healthy as possible, even with a cancer diagnosis. This means having a fair and just opportunity to receive all of the evidence-based care that we know makes a difference, as well as high quality care that matters from screening to the end of life.
Brielle Gregory Collins: Thank you so much for explaining that. And Dr. Hlubocky, talking about quality care, what does quality care mean in the context of cancer care?
Dr. Hlubocky: Thank you, Brielle. So according to the Institute of Medicine, now known as the National Academy of Medicine, quality care requires the safety, the efficacy, and the efficiency of care delivery. It's also timeliness and a patient-centered approach that's coordinated by an inter-professional oncology team with the integration of evidence-based or research-based practices to continually improve cancer care. It's a very comprehensive, a very value-based form of care that adheres to evidence-based guidelines. It assures the treatment of symptoms, and the side effects of cancer, and the cancer treatment. And it's also coordinated care with strong communication amongst all clinicians and patients, which might involve a written care plan that details all of cancer care, the care in a clinical trial, if that's a potential option for patients. And it also involves shared decision-making, including honest and frank discussion about prognosis, the intensive therapy, patient's values, and also preferences regarding care. As well, it's a research-based support for psychosocial needs. It provides palliative care throughout the course of treatment from diagnosis through the end of life, and end of life care involving hospice.
So quality cancer care was first coined by Dr. Joseph Simone, who was a pediatric oncologist and was the first, really, to advocate for quality-based cancer programs in pediatric oncology for both leukemia and lymphoma. And he was the one who truly started this movement that involves centering on every patient with cancer and every care program. So this year in Chicago at the Quality Care meeting, these interdisciplinary experts really highlighted the latest quality improvement research, as well as guidelines that helps us to improve the quality of cancer care from diagnosis through treatment to survivorship, and again, through end of life care.
Brielle Gregory Collins: Great. Thank you so much for walking through that. And yeah, we're excited to discuss more research from the Quality Care Symposium, too, a little later in this podcast. Dr. Patel, we know that health equity and quality care are linked. So how do health equity and quality care relate to better overall cancer care?
Dr. Patel: Great question. I love the fact that you brought up the Institute of Medicine's definition of quality because in my mind, doing work in health equity for over a decade now, really looking at health equity and quality, I've always thought of them as being intricately linked. But what I loved about the ASCO symposium and now some of the word choices that we're using, really does think that equity is not just a single component of quality, which previously it was. And now, the Institute of Medicine moved equity into being more of a cross-cutting dimension where it is an underpinning of all aspects of what Fay just outlined, in terms of effectiveness, safety, timeliness of care, etc. I think equity, in order to actually achieve high quality care, especially in the cancer realm, health equity has to be a fundamental component of such care. And so now, I'm going to take a step back because I think for years, we've been looking at equity as more of an issue of just access. But you heard in Fay's definition, and the definitions that are out there, that exist for quality, that equity and quality are not really just about access. In other words, differences in cancer care and inequity in cancer care is due to the fact that some populations, such as racial and ethnic minorities, for example, have poorer access to care than others. That is true, but this is just one factor, and it's not the only factor. Even when access is equal, we know that some populations tend to receive lower quality cancer care than others, be it by race and ethnicity, be it by socioeconomic status, gender identity and sexual orientation, or even age. So really, equal access does not equate to equitable care.
What's nice about linking quality and equity and this intricate linkage of the 2 means that you're addressing the effectiveness of the care. You're ensuring that, when you think of quality in terms of equity, the outcomes you're thinking about in terms of race and ethnicity and a…
playlist_add
Dec 1, 2022
Research Highlights from the 2022 North America Conference on Lung Cancer, with Xiuning Le, MD, PhD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Dr. Xiuning Le discusses new research on targeted therapy for non-small cell lung cancer presented at the 2022 North America Conference on Lung Cancer, held September 23-25 in Chicago, Illinois.
Dr. Le is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is also a 2022 Lung Cancer Advisory Panelist on the Cancer.Net Editorial Board.
You can view Dr. Le’s disclosures at Cancer.Net.
Dr. Le: Hi everyone. This is Xiuning Le. I'm an assistant professor here at MD Anderson in the Department of Thoracic/Head and Neck Medical Oncology department. I am a medical oncologist. I am a clinical investigator and also translational researcher. So today is a great opportunity to discuss some of the new meeting updates from 2022 North America Conference on Lung Cancer. Let me begin with the information about the meeting itself. So this conference, North America Conference on Lung Cancer, is organized by an organization called the International Association for the Study of Lung Cancer. As reflected in the name, this is an international organization for all the lung cancer researchers to get together to share our research, experience, and also patient advocates as well as patients participate in this fantastic organization. This organization also has meetings every year, including a World Lung Conference as well as the meeting we're going to talk a little bit about today, focusing on the progress we made in the North America. Therefore, it's called North America Conference on Lung Cancer. In this year's meeting, we had a very active agenda with multiple presenters from different parts of the U.S. And we also had international participants as well. We had exciting updates on some of the targeted therapy trials as well as updates from immunotherapy trials. So it was a very productive meeting.
Let me start with some of the updates from the targeted therapy space. During the meeting oral presentation, there were 3 abstracts selected for oral presentations. The first talk I would briefly discuss today is an update study for ADAURA trial using osimertinib as an adjuvant therapy for resected lung cancer patients whose tumor has EGFR mutation. This was presented by Dr. Roy Herbst, key investigator on the trial from Yale Cancer Center. So ADAURA trial is a multicenter international trial taking patients whose lung cancer have EGFR classical mutation at the diagnosis, or stage 1B to 3A, and then undergoing chemotherapy as the initial adjuvant treatment. But after completion of those treatments, patients were offered opportunities to go on to the trial receiving either osimertinib for 3 years or best supportive care placebo. The primary report of this trial became available in year 2021, where the osimertinib-treated patient had a significant clinical benefit reflected as the disease-free survival was much higher in the patient population who received osimertinib. The results of the ADAURA trial led to the FDA approval of using osimertinib in the surgically resected EGFR-mutant non-small cell lung cancer. So that's the background of this year's update and presentation.
Now, in the fall of 2022, after additional long follow-up, the data become more mature because although we still don't have overall survival results, we start to have 3-year disease-free survival. So in the study population, each is over 300 patients each arm, the 3-year disease-free survival rate was 84% for patients who receive osimertinib and then for placebo group is 34%. As you can see, this is a 2.5-fold significant benefit in the patient who received the treatment. The presentation was also a breakdown the patient population by their stage by different subgroup analysis across the board. The patient who received osimertinib derived benefit and then the hazard ratio remained to be between 0.2 to 0.3, depending which population we're looking at. Really, this data validated and confirmed the prior knowledge of this approach of offering adjuvant osimertinib really works and really should be offered to every single patient who qualifies for this study. One update on the subgroup analysis is the benefit for preventing brain metastasis to happen in the patients. Very impressive. We observe a hazard ratio of 0.24, meaning that if a patient goes on to osimertinib has a 4-fold benefit of not to develop brain metastasis. Overall, the conclusion of this presentation is that this data becoming more mature, and then the mature data reinforced that adjuvant osimertinib really should be the standard of care which we have been using pretty widely in the clinic.
The second abstract I want to talk about is a presentation that's presented by Dr. Lyudmila Bazhenova from University of California, San Diego. So she presented a pooled updated analysis on a novel EGFR exon 20 insertion medication. And then this medication currently is under U.S. FDA evaluation with breakthrough therapy designation. The drug's chemical name is called DZD9008, and then the drug's brand name is sunvozertinib. This is a great addition to the treatment option that we already start to see for EGFR exon 20 as a new inhibitor coming at the horizon. EGFR, we now start to classify all the mutations into classical mutation versus exon 20 mutation, as we are using different targeted therapy for different patients. For EGFR exon 20 insertion, we have already 2 FDA-approved drugs. One is amivantamab, the other is mobocertinib. But we still need more options for our patients. And this new medication, DZD9008, is having a great potential of becoming the next-generation EGFR exon 20 drug, as it showed good efficacy and pretty low toxicity.
So let's review the data that's presented here. In this meeting abstract, the authors combined 2 studies. One is called WU-KONG1. The other is called WU-KONG2. The first one was conducted in the U.S., and the second one was conducted in China. So there is a value of pooling different patient populations together and then not just getting the sample size greater but also understand different patient population, are they all having very similar benefit? Here the focus on analyzing the patient population that EGFR exon 20 lung cancer who have already received the chemotherapy. In the total of 71 patients analyzed here, in the subgroup of receiving 300 mg daily dose, the response rate was observed to be 40% to 45% depending on if you're using the central review system or you're using the investigator evaluation. But again, showing a very promising response. I want to put those numbers in the reference. For example, the currently FDA approved, the mobocertinib, in their population also had prior treatment. The response for mobocertinib was 28%. In the over 100 patient population, in these 71 patients, they see a 40% to 45% response. So potentially this one is having an even better efficacy really translate into clinic can be a great opportunity for the patients who had chemotherapy and needs something else. Also, we reviewed the toxicity profile. This drug is overall pretty well tolerated. We have to say that the population…
playlist_add
Nov 10, 2022
Research Highlights from ESMO Congress 2022, with David Ilson, MD, PhD, FASCO, Sumanta Pal, MD, FASCO, and Tian Zhang, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Cancer.Net Editorial Board members discuss new research in gastrointestinal and genitourinary cancers presented at this year’s ESMO Congress, held September 9-13 in Paris, France.
First, Dr. David Ilson discusses treatment advances in liver, colorectal, and gastric, or stomach, cancers. Dr. Ilson is an attending physician and member at Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.
You can view Dr. Ilson’s disclosures at Cancer.Net.
Dr. Ilson: Hi, I'm Dr. David Ilson from Memorial Sloan Kettering Cancer Center in New York. I'm a GI medical oncologist, and it's my pleasure today to review some important presentations in GI cancers from the recent ESMO meeting in Paris from 2022. I have no relevant relationships to disclose for this discussion. So, important presentations were made in hepatocellular cancer, in colorectal cancer, and gastric and other cancers, and I'm going to highlight some of the key presentations from the meeting.
One of the most anxiously awaited presentations was one in hepatocellular or liver cancer. For patients that have advanced disease who are not candidates for surgery or local treatments, standard therapy now, it used to be lenvatinib and sorafenib, and that's now been replaced by the combination of an immunotherapy drug, atezolizumab combined with the drug bevacizumab. That's the new standard of care. And recently, we had a promising data for another immunotherapy combination using the drug durvalumab combined with tremelimumab.
So what we saw this year was another important global study looking at the first-line use of immunotherapy in hepatocellular cancer. This trial took 794 patients with advanced hepatocellular cancer and assigned them to a standard treatment with a drug called lenvatinib. Lenvatinib and sorafenib were the old standard treatments for hepatocellular cancer. And lenvatinib alone was compared to a combination of lenvatinib and pembrolizumab, an immunotherapy drug. The primary endpoint was to see whether adding immunotherapy to lenvatinib improved survival. And this was a negative trial. It did not show an improvement in survival for adding pembrolizumab to lenvatinib over lenvatinib alone, and there was really no significant difference in the time that patients were on treatment. The response was slightly higher with the addition of pembrolizumab to lenvatinib, but again there was no survival difference. So this combination will not move forward. And again, as I said earlier, the new standard first-line treatment is atezolizumab plus bevacizumab.
In colorectal cancer, probably one of the most exciting presentations was the use of immunotherapy treatments in locally advanced colon cancer. There is an important subset of colorectal cancer that has what's called an MSI-high status. MSI-high colon cancers are very responsive to immunotherapy drugs, and there has been a lot of interest in patients with localized colorectal cancer using immunotherapy drugs prior to surgery rather than conventional chemotherapy or radiation. So this important trial looked at 112 patients with localized colorectal cancer. Most of the patients were stage 3, and they all were documented to have this MSI-high status, which indicated a higher chance of response to immunotherapy. And patients received a brief course of immunotherapy, 2 doses of the drug nivolumab combined with 1 dose of ipilimumab over only 6 weeks followed by surgery. What they showed in these 112 patients who went to surgery, there was almost 100% response to this treatment. In fact, almost two-thirds of patients had no cancer found at surgery, even only after several weeks of immunotherapy. And in the 112 patients treated, there have been no recurrences in any of these patients.
So it's quite remarkable that immunotherapy could induce a complete remission in two-thirds of patients, and that was only after a few weeks of exposure of the drug. So I think we're going to see more interest in using immunotherapy treatments as a potential pre-surgical treatment for colon cancer. And we could argue with such a high rate of complete remission, if we gave immunotherapy longer, maybe we could consider nonsurgical management, to just keep treating the patients with immunotherapy. This is actually the case that's now been seen in rectal cancer, a recent study presented from my institution where they treated patients with rectal cancer with immunotherapy, and we also achieved 100% remission, and none of the patients in this small study required surgery. So I think this important study, which is called the NICHE-2 trial, indicates a high degree of effectiveness of immunotherapy in MSI-high colon cancers. And certainly, it raises interest in using this as a preoperative treatment and potentially could lead to some patients getting treatment with immunotherapy alone without surgery.
Then I'm going to comment a little bit about advanced metastatic colon cancer. Another important presentation was studying a new drug called fruquintinib. Fruquintinib is an oral drug that targets the VEGF pathway, which is an angiogenesis pathway in colon cancer. Standard treatment for colon cancer when it's stage 4 disease is now use of chemotherapy, like FOLFOX and FOLFIRI, drugs like bevacizumab, cetuximab, and panitumumab. And in more chemotherapy-resistant cancers, we use drugs like regorafenib and TAS-102. So this trial looked at a large group of patients, over 690 patients who had received all conventional treatments. They had progressive disease on all conventional treatments, including the late-line drugs regorafenib and TAS-102. And this was a placebo-controlled trial in which patients either received the drug fruquintinib or they received placebo plus supportive care. It was reasonable to offer a placebo in this trial because there really was no other standard treatment option for these patients. The primary endpoint of overall survival was improved with fruquintinib. Survival was improved with a reduction in the risk of death by about 30% and improvement in time on treatment. Very few patients responded to fruquintinib, so this was largely a drug that stabilized the cancer, but it did lead to modest improvements in time on treatment and modest improvements in survival. So this drug may potentially be evaluated as a new treatment option in very chemotherapy-resistant colorectal cancer.
I just want to mention briefly another new class of agents for which we had data presented at the ESMO meeting. These are drugs that inhibit a mutation in their cancer called KRAS G12C. There are promising drugs that target this pathway. And there were 2 drugs that were followed up on at ESMO, one was a drug called sotorasib and another drug was adagrasib. These are drugs that target KRAS G12C mutations in colon cancer. And both of the trials that were presented used these drugs combined with drugs that target the EGFR pathways, so either panitumumab or cetuximab, and very encouraging responses were seen on these trials. The trial that looked at the combination of adagrasib plus cetuximab achieved a response in about 46% of patients, which is very…
playlist_add
Oct 6, 2022
Making Metastatic Breast Cancer Clinical Trials More Inclusive, with Stephanie Walker, RN
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
At the 2022 ASCO Annual Meeting, registered nurse, breast cancer survivor, and patient advocate Stephanie Walker presented the results of the BECOME Research Project, which looked at Black patient participation in metastatic breast cancer clinical trials.
In this podcast, Ms. Walker shares her story with Dr. Manali Patel, a medical oncologist and Assistant Professor of Medicine at Stanford University, as well as the Cancer.Net Associate Editor for Health Equity. They discuss Ms. Walker’s experience with metastatic breast cancer, how she became involved with patient advocacy and research, and the work being done within the oncology community to make cancer clinical trials more equitable and inclusive.
View disclosures for Ms. Walker and Dr. Patel at Cancer.Net.
Dr. Manali Patel: Hello, I'm Manali Patel. I'm a thoracic lung cancer doctor at Stanford University and the VA in Palo Alto. And I'm a researcher that's focused on trying to improve and overcome health disparities and really trying to achieve health equity. I'm also the Cancer.Net Associate Editor for Health Equity. And today it's my great pleasure to talk with Ms. Stephanie Walker. Stephanie is a registered nurse, a survivor of metastatic breast cancer, and a leading patient advocate. She's the lead author of the BECOME Research Project on increasing Black patient participation in metastatic breast cancer clinical trials, which she presented beautifully at the 2022 ASCO Annual Meeting. Stephanie, we can't thank you enough for talking with us today. I'm going to first start off by saying that I am from North Carolina. And Stephanie, I read so much about you over the past few years and noticed that you are living in Tarboro, North Carolina. Is that correct?
Stephanie Walker: That is correct. I currently live there. We moved here originally in 2012, but this is my, I think, third or even fourth time living in North Carolina, moving back and forth between Thomasville and Durham and now permanently in Tarboro.
Dr. Manali Patel: Well, I love that we share our Tar Heel roots. I am a Tar Heel born, Tar Heel bred. When I die, I'm a Tar Heel dead. So I can't thank you enough for sharing those roots and then also for sharing your story with us today. You were first diagnosed with metastatic breast cancer in 2015. Can you tell us a little bit about your experience with that diagnosis and what it was like to be diagnosed?
Stephanie Walker: Well, actually the diagnosis in 2015 was my first diagnosis. I was not an early stager that had a recurrence, so I guess I could say breast cancer was never on my radar regarding family history. I thought maybe kidney disease or hypertension or those kind of things, but never breast cancer. So to say my life derailed at that time, it had. And I don't know if I ever grieved when I was told that I had metastatic breast cancer, I took it and just ran with it. I did not really fall off until many years later when I had to stop working. At the time I was diagnosed, I was working as an on-call nurse for a hospice company. So I was working 7 days on, 7 days off. So on my 7 days on is when I received a call and during my nap time. But yeah, it was very hard.
But like I said, I didn't think bad of it. When I did finally look it up and see that the life expectancy was like 36 months, that kind of kicks your butt into gear to do things. But I didn't do anything. I just continued to work. [laughter] I didn't stop working. So yeah, it went through the basic standard of care treatment of Adriamycin, Cytoxan, and Taxol. But I didn't get through my whole series of Taxol due to neuropathy and increased falls. So I stopped at 9 out of 12.
Dr. Manali Patel: Still 9 out of 12, it's difficult. And that's a difficult therapy and difficult regimen. You talked about how it derailed your life. And I know I've had the pleasure of reading your story online. I think what's also really interesting is that you had a role as a hospice nurse and over 40 years as a hospice nurse.
Stephanie Walker: No, most of my years of nursing was critical care. The last 14 years were hospice care, palliative life care. But, yeah, I just rolled with that. Even taking care of patients that had the same diagnosis kind of brought-- seeing death and dying every day. But then to see somebody with metastatic breast cancer dying was really hard.
Dr. Manali Patel: Yeah. And I'm sure that your experience at nursing on the other side and the flip side, and then when you became a patient, is quite different and maybe challenging in and of its own.
Stephanie Walker: A lot of people expected or said that. I think I got left out of a lot of things that could have helped my journey in the beginning, like a patient navigation and that kind of thing was kind of not given to me. And I guess it was because being a nurse. But I had no experience other than pediatric oncology. I knew what those children went through. And actually, it actually did help going through my treatment because I would remember this one little girl that was going through chemo, and she got up one morning and her pigtails started falling out, and then she wanted to get on the IV pole and go to the playroom. And I'm thinking to myself, if she can do it-- and I called her by name, if she can do it, what the hell am I complaining about? So it's like, just get up and go to the playroom. [laughter]
So I kept going back to that, you know what I mean? These kids that are innocent and have not even started to live their life going through this, and they never complained. So being an old lady at 56, being diagnosed, hell, who was I to complain about it? So just pick your hair up and keep going.
[laughter]
Dr. Manali Patel: That's right. Get your IV pole and go to the playroom.
Stephanie Walker: That's right.
Dr. Manali Patel: It's interesting that you mentioned that being from the nursing field and from the medical field kind of excluded you from a lot of what we hope other people receive, which is good education about their diagnosis. And like you mentioned, a patient navigator. Do you think that being a Black woman in any way, shape, or form shaped your experience with cancer, and if so, how?
Stephanie Walker: It didn't in the beginning. Like I said, from 2015 up until 2018 when I found myself suddenly without a job or insurance, I had no idea. I didn't know anybody else with metastatic breast cancer. I didn't know what was out there. I guess I didn't have a need that was not met. I had insurance that was paying the bills. I had a husband that helped care for me, 2 adult children that looked in on me, a job that I didn't consider a job, it was a calling, and I had no needs at that time that weren't met. So I didn't have the desire or the need to look outside my little tiny world, I guess, until I found myself in 2018. In 2017, we moved late in the year back to North Carolina from Louisiana and started a new job as a hospice nurse, same kind of a schedule and was out shopping with my husband one day, and I kept saying, "I'm really short of breath." And I said, "All this weight I've gained since treatment, it's horrible. I'm just fat and can't breathe." And he just kind of la…
playlist_add
Sep 15, 2022
2022 Research Round Up: Lung Cancer, Lymphoma, and Childhood Cancers
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s episode, our guests will discuss new research in lung cancer, lymphoma, and childhood cancer that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois.
First, Dr. Charu Aggarwal will discuss 3 studies looking at treatment options for people with non-small cell lung cancer.
Dr. Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the Cancer.Net Associate Editor for Lung Cancer.
You can view Dr. Aggarwal’s disclosures at Cancer.Net.
Dr. Aggarwal: Hello and welcome to this Cancer.Net podcast. I'm bringing you updates from the Annual Meeting of the American Society of Clinical Oncology, held in Chicago in 2022. I'm Dr. Charu Aggarwal. I'm the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania's Abramson Cancer Center. I will be discussing updates on 3 studies today that offer insights and new advances in the management of patients with non-small cell lung cancer. I don't have any direct relationship with any of these companies or studies, and you can view a list of my disclosures on the Cancer.Net website.
First off, I would like to talk a little bit about advances in the management of patients with EGFR exon 20 mutations. We know that a lot of advances have been made in the management of patients with non-small cell lung cancer, and much of that has been attributed to the fact that we are now able to deliver targeted therapy for a subset of patients. EGFR mutations form one such subset where we have a lot of oral drugs that are available, and we can offer these that improve survival, and patients can avoid chemotherapy, immunotherapy, and other IV infusional therapies. Within the subset of EGFR mutations lies this unique subset of EGFR exon 20 insertion mutations, which have been historically harder to target with currently available EGFR inhibitors. And over the last 5 years, we have seen tremendous growth of opportunities, targets, and new drugs for this subset of patients. The mutations in this subset forms about 2% to 5% of all non-small cell lung cancers. But now we have 2 FDA-approved drugs in this space, one being intravenously administered, amivantamab, and another that is orally available, mobocertinib. We covered this in a podcast as well as a blog, so please check those out on our Cancer.Net website.
But building upon that progress, there is now another drug that was reported at ASCO. This drug is called CLN-081. And we saw preliminary activity in a phase 1 and 2 study of this molecule or this drug in patients with EGFR exon 20 insertion mutations. It's an orally available drug. The top line data is that it is safe, it is effective, it was tested in different doses. It was tested at less than 65 milligrams, 100 milligrams, and 150 milligrams, again, as I mentioned, administered orally, and we saw responses and patients that had previously received other therapies and may have progressed on other therapies. And what we found was that this drug also tends to have activity against brain metastases, which I think is this huge unmet need in the management of such patients. So I think more to come, but again, I think offers us an insight into what may be in the future, an attractive drug for our patients with EGFR exon 20 insertion mutations. So stay tuned, more on that in the future.
Shifting gears, I would like to now talk about one of the common mutations. So we talked about EGFR exon 20, which is about only 2% to 5%, but the largest subset of mutations in non-small cell lung cancer really revolves around KRAS mutations, and these form about 30% to 35% of all mutations in non-squamous, non-small cell lung cancer. And amongst this group there is another subset which is KRAS G12C non-small cell lung cancer, that forms about 13% of all lung cancers. We have 1 approved drug already in this space by the name of sotorasib that is FDA approved for the management of patients with this particular mutation after having received 1 prior therapy, be it chemo-immunotherapy or immunotherapy. At this year's ASCO meeting, we heard data from a study called KRYSTAL-1, which looked at the activity and safety of another molecule called adagrasib, which is an orally available drug targeting KRAS G12C, again, in a similar population of patients with advanced and metastatic non-small cell lung cancer harboring a mutation.
We found that this drug is again effective, the overall response rate was about 43%, the majority of the patients had stabilization of disease, about 80%, and many patients were able to remain on treatment with stabilization of disease. We found that this drug does have side effects and adverse events and most commonly of this were diarrhea, nausea, vomiting, and fatigue. Many patients did require dose reductions, but the activity of the drug remained despite dose reductions. Now, what would be the advantage of this drug against the currently available sotorasib? In another smaller study reported at ASCO, there seemed to be activity in the brain, including intracranial penetration with the use of this molecule, adagrasib, which has not been demonstrated before with other KRAS G12C inhibitors, so I think that makes it a potentially attractive option. Again, I will say that the report of this intracranial activity was in a very small subgroup of patients, so I think needs to be further corroborated in a larger study.
Shifting gears again and talking about our last study, so I would like to highlight what do we do if, in case, patients don't have a targetable mutation. I want to highlight that we do have a lot of available options, and we are continuing to improve upon available options. The way we treat such patients is by using immunotherapy, either alone or in combination with chemotherapy. But what do we do after this treatment stops working? Researchers from the Southwestern Oncology Group, or SWOG, launched a massive national effort called Lung-MAP, which is basically a clinical trial that evaluates several different strategies all at once, either for patients with targetable mutations or for patients without a targetable alteration. And they reported results from a study that evaluated the combination of pembrolizumab with ramucirumab in patients that may have progressed after frontline immunotherapy. Now, pembrolizumab is immunotherapy, so the concept was, can we continue immunotherapy beyond progression and perhaps get some synergistic activity by using ramucirumab, which is a drug that prevents blood vessels from forming in the tumor itself. It's an anti-angiogenic agent, meaning that it is a targeted molecule that prevents blood vessel formation and promotes tumor death. What they found was that patients that received pembrolizumab and ramucirumab were more likely to live longer, so overall survival was l…
playlist_add
Sep 1, 2022
Highlights from the 2022 MASCC Annual Meeting, with Maryam Lustberg, MD, MPH
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Dr. Maryam Lustberg discusses highlights from the Multinational Association of Supportive Care in Cancer’s 2022 Annual Meeting, held June 23-25 in Toronto.
Dr. Lustberg is the Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center; Chief of Breast Medical Oncology at Yale Cancer Center; Associate Professor of Medicine at Yale School of Medicine; and the 2022 President of the Multinational Association of Supportive Care in Cancer. She is also a member of the Cancer.Net Editorial Board.
View Dr. Lustberg’s disclosures at Cancer.Net.
Dr. Lustberg: Hello, everyone. I'm Dr. Maryam Lustberg. I am chief of breast oncology at Yale Cancer Center, co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the new president of the international society of Multinational Association of Cancer Supportive Care, or MASCC. And I'm here to talk to you about updates from the meeting that happened in Toronto in June of 2022. I have no relationships to disclose relevant to the topics that I will be talking about today.
And there were 3 broad themes in the meeting that I would like to highlight for you. One theme was a global focus on disparities in the delivery of cancer supportive care. So we do know that even in North America, patients with different socioeconomic backgrounds, different races, different cultural backgrounds, may not have as full access to cancer supportive care services, and that can include access to symptom management, survivorship care, palliative care. The umbrella of cancer supportive care is quite broad, and it's really focused on supporting patients and their families throughout the care continuum in a very multidisciplinary, holistic way. And so what we're finding, unfortunately, similar to cancer treatment, access to the best supportive care in cancer can also face certain disparities in the U.S. and North America. And this is something that we talked quite a bit about in the meeting in terms of recognizing this as well as finding solutions for it. And similarly, globally, we know that access to symptom management strategies, access to palliative care, access to oncology rehab, all of these can be quite restricted in different regions of the world. So the meeting in Toronto was really a call to action to recognize this as a pressing issue for our global community. And we will be forming several task forces to really look towards solutions. And so we look forward in terms of looking at low-hanging fruit interventions that we can both provide in North America as well as globally so that really patients and families could have access to such an important part of cancer care.
The second theme of the meeting focused on digital technologies as well as the impact of COVID-19 on the delivery of cancer supportive care. We know that the pandemic certainly shook the world, and it also impacted patients' access to supportive care services. These were often the services that were put on hold, understandably, during the resource-lean times and restricted access to services during the pandemic. So this was something that we absolutely recognize that this happened. It impacted many patients and families, but we also, as a community, really came together to come up with innovative solutions. And one of these innovative solutions, what people have called maybe the silver lining in what happened during COVID, is that there was an increase in telehealth services, including telehealth care delivery of some of these supportive care services. So a lot of the meeting focused on how this was implemented, what access may have looked like. There's certainly disparities even here in terms of access to telehealth services. And also patient preferences and caregiver preferences also plays a great role here, where some patients really find telehealth to be a really comfortable solution for them. They don't have to leave their home, find parking, but others may find it less personal. So really, if we're thinking about personalizing cancer supportive care, I think there was a lot of discussion about making sure that we kind of understand which clinical situations may benefit from telehealth care delivery, which situations may do better with face-to-face, and ultimately to really involve patients and families in that decision and to make sure that we're engaging and not dictating policies without their full engagement. So this is something that we absolutely care deeply about.
The third theme focused on burnout. There was a lot of focus on clinician burnout, which we know was also something that was a tremendous issue during the pandemic due to workforce shortage across all health care disciplines. People have talked quite a bit about the great resignation, where many health care workers as well as people in other sectors actually resigned or could not work in the conditions that the pandemic necessitated. So there was a lot of focus on recognizing burnout in clinicians because that directly impacts how well we can take care of patients. So recognizing it and thinking about proactive solutions, including there was a wonderful speaker, Dr. Benjamin Corn, who has done quite a bit of research on hopefulness and really feeling hope, whether you're a caregiver, whether you're a clinician or a patient, was found to be a key measure or predictor of burnout. And this is not meant to minimize system issues or anything like that. But I think there was a lot of focus on self-management and self-efficacy, kind of recognizing burnout and trying to foster things that we can do ourselves to keep ourselves healthy mentally, emotionally, and spiritually so that we can continue to function in the health care setting and take the best care of our patients, which is ultimately our goal as an entire scientific oncologic community is to be more present, to be more engaged, to deliver the best evidence care whether it be in the realm of cancer treatments or cancer supportive care, I do feel it's all part of that full package. Thank you so much for listening to this podcast.
ASCO: Thank you, Dr. Lustberg. You can find more research from recent scientific meetings at www.cancer.net.
Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care.
And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology.
Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.
playlist_add
Aug 25, 2022
2022 Research Round Up: Head and Neck Cancer, Brain Tumors, and Health Equity
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s episode, our guests will discuss new research in head and neck cancer, brain tumors, and health equity that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois.
First, Dr. Cristina Rodriguez will discuss 2 studies on new treatment options for locally advanced head and neck cancer.
Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the Cancer.Net Associate Editor for Head and Neck Cancers.
You can view Dr. Rodriguez’s disclosures at Cancer.Net.
Dr. Rodriguez: Hello. My name is Christina Rodriguez. I'm a medical oncologist with a clinical and research focus on head and neck cancer. And today I'm going to discuss research on head and neck cancer that was presented at the most recent 2022 ASCO Annual Meeting. I don't have any relationship to disclose that pertains to the research that I will talk about today. I'd like to discuss 2 abstracts that I thought were practice changing or practice affirming that really addresses some of the key questions that patients and doctors like me have about the treatment of patients with head and neck cancer. So, as you know, most patients with head and neck cancer present with typically locally advanced disease, and most head and neck cancer patients are treated with the intent of curing them most of the time with the use of radiation either as the main treatment or after surgery. And many clinical trials have shown that when we add a chemotherapy called cisplatin to radiation, we improve curative outcomes for patients.
But the first abstract that I will talk about, abstract 6003, asks the question "What do we do for patients who are not candidates for cisplatin chemotherapy?" And we know that a significant proportion of our patients will have other medical problems that could make it difficult for us to give chemotherapy and often will result in complications or more toxicity or in side effects for patients. This clinical trial was carried out in India, and it compared radiation alone for patients with head and neck cancer versus radiation given with a non-cisplatin chemotherapy called docetaxel. What's unique about this clinical trial is that it's specifically focused on patients who were not candidates for cisplatin chemotherapy, something that really hasn't been done for this population. Interestingly enough, they found that when we give docetaxel with radiation in these patients, we find that they do better, they live longer, and they feel better based on quality-of-life questionnaires.
So I will say that this study, abstract 6003, tells us that even in patients who are not candidates for cisplatin to be given with radiation, there is an alternative treatment that we can use, such as docetaxel given with radiation, that might still improve patient's cure rates for their head and neck cancer.
The second study that I think was another interesting study was a clinical trial that asked the question, "Can we give cisplatin in an alternative manner for patients who are undergoing definitive radiation treatment as their main treatment for head and neck cancer?" Like I mentioned, the clinical trials that led to the use of chemoradiation as a standard use cisplatin given in larger doses every 3 weeks, but there's been concern about how well that approach is tolerated by patients. So this particular clinical trial compared patients receiving radiation as curative intense therapy for head and neck cancer with either the cisplatin given every 3 weeks or the cisplatin given at a lower dose once a week.
It's important to know that this trial was done in India, where the population is pretty different from what we see in the United States. These are mostly patients who have HPV-negative cancers, mostly cancers acquired through exposures like tobacco and alcohol. And what they found was that these 2 groups of patients had very similar outcomes. In other words, there didn't seem to be a reduction in the rates of cure when we give chemotherapy every week versus every 3 weeks. And interestingly enough, it looked like from a toxicity or side effect standpoint, the every week seems to be a little bit better tolerated. Patients who got the treatment every 3 weeks also had less need for hospitalization or IV fluids and less utilization of health care resources.
I think this is a very interesting finding because it really provides us with what we call high-level data that the weekly administration can work. I think it's important to recognize that the population that it studied for this particular clinical trial really was more an HPV-negative population. That's important to know because the standards for HPV-positive head and neck cancer are generated from larger trials that use cisplatin every 3 weeks. But we are continuing to study this question, and there's actually a large NRG study, HN009, that is asking that question both for the HPV- positive and HPV- negative population. So we are, I think, making strides in terms of asking the questions that allow our patients not only to receive treatment that is highly efficacious but also that limits side effects and toxicity. I will also mention that these trials were completed during the COVID-19 pandemic, which tells you that the dedication of these researchers to complete something like this in such a challenging time is to be commended. That's all I have to say, and thank you for listening to this brief summary of new research in head and neck cancer from the ASCO 2022 Annual Meeting.
ASCO: Thank you, Dr. Rodriguez.
Next, Dr. Glenn Lesser will discuss 3 studies that looked at new treatments for different types of brain tumors.
Dr. Lesser is the inaugural Louise McMichael Miracle Professor and Associate Chief in the section on Hematology and Oncology in the Department of Internal Medicine at Wake Forest Health. He is also the Cancer.Net Associate Editor for Central Nervous System Tumors.
You can view Dr. Lesser’s disclosures at Cancer.Net.
Dr. Lesser: Hello. My name is Glenn Lesser, and I'm a professor of medical oncology and the director of medical neuro-oncology at the Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, North Carolina. I'm also the editor of the brain tumor section for ASCO's Cancer.Net. And today, I would like to briefly discuss several clinically relevant research studies involving patients with brain tumors that were presented at this year's ASCO Scientific Program. Of note, I have no disclosures or relationships relevant to the abstracts I'll be discussing today.
The first presentation to talk about is a late-breaking abstract presented by Dr. Eric Bouffet, who described the results of a phase II trial of 2 targeted anticancer agents, dabrafenib and trametinib, in pediatric pat…
playlist_add
Aug 18, 2022
Coping with Cancer Through Exercise, with Sheila Lahijani, MD, and Sami Mansfield
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clinical Oncology. Today we're going to be talking about coping with the mental and emotional challenges of cancer through exercise. Our guests today are Dr. Sheila Lahijani and Sami Mansfield. Dr. Lahijani is an associate clinical professor of psychiatry and behavioral sciences at the Stanford University School of Medicine and the medical director of the Stanford Cancer Center Psychosocial Oncology Program. Dr. Lahijani is also an advisory panelist on the Cancer.Net Editorial Board. Thanks for joining us today, Dr. Lahijani.
Dr. Sheila Lahijani: It's truly my pleasure to be here today, Brielle, with all of you.
Brielle Gregory Collins: Thank you. Ms. Mansfield is the founder of Cancer Wellness for Life and the director of Oncology Wellness for the Sarah Cannon Cancer Institute at HCA Midwest Health. Thanks for joining us today, Ms. Mansfield.
Sami Mansfield: Thanks, everybody, for having me. Excited to be here as well.
Brielle Gregory Collins: Before we begin, we should mention that Dr. Lahijani and Ms. Mansfield do not have any relationships to disclose related to this podcast, but you can find their full disclosure statements on Cancer.Net. Now to start, Dr. Lahijani, how can a cancer diagnosis impact a person's mental and emotional well-being?
Dr. Sheila Lahijani: Thanks for asking this question, Brielle. Usually, when people want to know the answer to this, what I preface it by saying is that there is a spectrum of responses. Many people find themselves to be quite distressed because cancer continues to have quite a lot of stigma, both in this country and as well as internationally. People oftentimes associate it with feelings of despair, anxiety, and helplessness. Having said that, many of these responses and reactions are normal. Some people can progress to have many more significant emotional responses and reactions that can become more disruptive to their lives and to the roles that they play a part in. We really try to meet patients where they're at to better understand how they've previously coped with past life challenges and/or traumas and to identify what strengths they have, what coping mechanisms they have to help them manage the distress associated with cancer. There are patients who also have a history of past psychiatric diagnoses and problems, in which case getting diagnosed with cancer and undergoing cancer treatment can cause a lot more difficulty. So each person is different. There are a lot of, quote-unquote, "normal" reactions, responses and reactions, that we as providers do validate and reflect back to the patients. And then there are those that can cause many more problems, and those are the ones we really need to address.
Brielle Gregory Collins: Okay. And getting into some of those problems, what are some of the most common mental and emotional challenges that people face during cancer?
Dr. Sheila Lahijani: The majority of people feel very anxious. And I've shared this with others and share this with my patients: being anxious means something. It means that you care about something. You care about yourself. You care about your life. You care about people in your life. And so it's a sign. It's something that needs to be tended to. People suffer from mood symptoms such as depression as well, difficulty coping, feelings of loss and despair. Those are the most common reactions. Some people can develop other difficulties related to side effects of cancer treatments as well. And also, there are people, as I mentioned, who previously have suffered from psychiatric symptoms, where things can become much more difficult and challenging, affecting their way of thinking: problems with cognition, memory, recall, things like that. So to summarize, largely mood disturbances and mood symptoms in the forms of anxiety and depression. Panic is also a part of that, as well as post-traumatic stress. And there are others who have previous symptoms that can become more problematic. So we really try to evaluate both mood and thinking in our patient population.
Brielle Gregory Collins: Thank you so much for walking through those. And I want to talk a little bit now about exercise and how that can play a role in coping with some of these challenges. Ms. Mansfield, what is considered exercise, and what are some of the benefits of exercising during cancer?
Sami Mansfield: Great question because there are so many different terminologies around exercise and physical activity and fitness. So I think we should start there. The terminology of physical activity is probably the most broad thing that we talk about. Physical activity is anything that we do to move the body, anything from rolling over in bed, getting up, brushing your teeth, etc. Exercise is a physical activity that is more defined or maybe has a purpose. And so it might be a goal to get stronger or a goal of rehab or prehab in this particular patient population. Or some people just want to be able to walk a 5k or run a 5k. So exercise is more intentional. And that's really how we try to define it in the literature.
From a cancer patient perspective, probably the most broadly impactful side effect management tool for exercise is actually fatigue because that is where we have a depth of evidence both in physical activity and inactivity differences. And related to fatigue from the mental health side, we see a strong benefit of both exercise and physical activity in anxiety, depression, stress management, sleep quality. So I think it's important for our audience to know that anything that you do for movement is good. Having a planned and structured movement program known as exercise is going to be ideal because the bottom line is we want you to reach your goal the quickest and without kind of feeling like you're not getting a lot of benefit to movement. And so that's why exercise really does have a significant role and why I think a lot of people really strive for, "What should I do? What does that specific exercise plan look like?"
Brielle Gregory Collins: Got it. And I want to circle back to some of the challenges, Dr. Lahijani, that you outlined earlier. So how does exercise help address some of these challenges of cancer specifically?
Dr. Sheila Lahijani: Well, I love this question. And I'm very informed by what my colleague, Ms. Mansfield, just described. Exercise and physical activity, in my opinion, are so beneficial to patients who are already diagnosed with cancer, as well as those patients who may be at risk for developing cancer-- any of us, really, to reduce our risk for certain kinds of cancer. There have been many studies that have been done that have demonstrated that intentional physical activity, as my colleague termed it, in the form of exercise can ramp up certain biological processes that contribute to improvements in cognition as well as memory function. There's a factor called a “brain-derived neurotrophic factor” which can get increased wi…
playlist_add
Jul 28, 2022
2022 Research Round Up: Multiple Myeloma, Breast Cancer, and Cancer in Adults 60 and Over
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with c…
playlist_add
Jul 21, 2022
Reflecting on COVID-19 and Providing Reliable Information to People with Cancer, with Merry Jennifer Markham, MD, FACP, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
The beginning of the COVID-19 pandemic brought with it confusion, fear, and uncertainty for most people around the globe. These feelings were often heightened for people with cancer as they experienced disru…
playlist_add
Jun 30, 2022
2022 Research Round Up: Prostate, Testicular, Bladder, and Kidney Cancer
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today…
playlist_add
Jun 15, 2022
Molecular Testing for Early-Stage Non-Small Cell Lung Cancer, with Ryan Gentzler, MD; Xiuning Le, MD, PhD; Brendan Stiles, MD; and Vamsidhar Velcheti, MD, FACP, FCCP
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, members of the Cancer.Net Editorial Board discuss new research in molecular testing, also known as biomarker testing or tumor marker testing, to help guide treatment for people with early-st…
playlist_add
May 27, 2022
Understanding Clinical Practice Guidelines, with Jeffrey Meyerhardt, MD, MPH, FASCO, and Scott Tagawa, MD, MS, FACP
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast.…
playlist_add
May 10, 2022
Navigating the Challenges of Gynecologic Cancer Survivorship, with Fay J. Hlubocky, PhD, MA, and Merry Jennifer Markham, MD, FACP, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast.…
playlist_add
Mar 31, 2022
Research Highlights from the 2022 Multidisciplinary Head and Neck Cancers Symposium, with Kedar Kirtane, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Dr. Kedar Kirtane discusses new research from the 2022 Multidisciplinary Head and Neck Cancers Symposium, held February 24-26 in Phoenix, Arizona,…
playlist_add
Mar 3, 2022
Understanding Somatic Genomic Testing in People with Metastatic or Advanced Cancer
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
Greg Guthrie: Hi, everyone. I'm Greg Guthrie, and I'm a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is…
playlist_add
Feb 3, 2022
Research Highlights from the 2021 American Society of Hematology Annual Meeting, with Christopher Flowers, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In this podcast, Dr. Christopher Flowers covers highlights from the 2021 American Society of Hematology Annual Meeting, held December 11 to 14 in Atlanta, Georgia.…
playlist_add
Jan 20, 2022
Research Highlights from the 2021 San Antonio Breast Cancer Symposium, with Norah Lynn Henry, MD, PhD, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests statements on this podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry will discuss new research presented at the 2021 San Antonio Breast Cancer Symposium, held Decembe…
playlist_add
Dec 16, 2021
Targeted Therapy for Non-Small Cell Lung Cancer with an EGFR Exon 20 Insertion
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, experts will discuss targeted therapy for lung cancer, including 2 new treatments that target a specific type of mutation or change in the EGFR gene in some cancer cells, called an EGFR exon 20 insertion. They will e…
playlist_add
Nov 1, 2021
Understanding Side Effects of Immune Checkpoint Inhibitors, with Tian Zhang, MD, MHS, and Afreen Idris Shariff, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
In this podcast, Dr. Tian Zhang and Dr. Afreen Shariff discuss common and sometimes serious side effects caused by a type of immunotherapy called “immune checkpoint inhibitors.” They also explain why it is important for people with cancer to track the side effects they experience and discuss them with their health care team.
Dr. Zhang is an a…
playlist_add
Sep 30, 2021
2021 Research Round Up: Brain Tumors and Gastrointestinal Cancers
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s episode, Cancer.Net Ass…
playlist_add
Sep 2, 2021
Talking with Your Children About Your Metastatic Cancer Diagnosis and Prognosis, with Eliza Park, MD, and Paula Rauch, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American So…
playlist_add
Aug 16, 2021
2021 Research Round Up: Gynecologic Cancers, Melanoma, and Cancer in Adults 65+
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s episode, 3 Cancer.Net A…
playlist_add
Aug 5, 2021
2021 Research Round Up: Lung Cancer, Breast Cancer, and Sarcomas
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s episode, 3 Cancer.Net A…
playlist_add
Jul 22, 2021
Understanding Social Determinants of Health, With Karen Winkfield, MD, PhD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American So…
playlist_add
Jun 23, 2021
2021 Research Round Up: Prostate, Bladder, Kidney, and Testicular Cancers
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today’s podcast, 4 Cancer.Net S…
playlist_add
Jun 9, 2021
Kidney Cancer Genetic Conditions and Genetic Counseling, with Brian Shuch, MD, and Lauren Bear, MS, LCGC
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Brielle Gregory Collins: Hi, everyone. I'm Brielle Gregory Collins, a member of the Cancer.Net Content Team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American So…
playlist_add
May 20, 2021
Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, KEYNOTE-991
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Mar 11, 2021
Addressing Mental Health Issues in Adolescent and Young Adult Survivors, with Lidia Schapira, MD, FASCO, and Daniel A. Mulrooney, MD, MS
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Dr. Lidia Schapira and Dr. Daniel Mulrooney discuss a study published in the Journal of Clinical Oncology about mental health outcomes for AYA cancer survivors and how young survivors can get the mental health suppor…
playlist_add
Jan 29, 2021
Research Highlights from the 2020 San Antonio Breast Cancer Symposium, with Norah Lynn Henry, MD, PhD, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry discusses new research presented at the 2020 San Antonio Breast Cancer Symposium, held virtually December eighth through eleventh. Dr. Henry is an Associate Professor…
playlist_add
Jan 15, 2021
Lymphoma Highlights from the 2020 American Society of Hematology Annual Meeting, with Michael E. Williams, MD, ScM
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams talks about new research and advances in the field of lymphoma, including 3 recent U.S. FDA drug approvals. The research discussed was presented at the 2020 American S…
playlist_add
Dec 21, 2020
Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, CYTOSHRINK
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Nov 30, 2020
Health Disparities and Cancer Clinical Trials, with Petros Grivas, MD, and Edith P. Mitchell, MD, FACP
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Cancer does not affect all people equally. Some groups of people, including racial and ethnic minorities, poor people, sexual and gender minorities (LGBT+ people), adolescent and young adult populations, and older adults, are more li…
playlist_add
Nov 12, 2020
New Research from the SIOG 2020 Annual Meeting Online, with William Dale, MD, PhD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Dr. William Dale will discuss new research presented at the International Society of Geriatric Oncology 2020 Annual Meeting, held virtually on October 1st.
Dr. Dale is director of the Center for Cancer and Aging Res…
playlist_add
Nov 9, 2020
Making Decisions for a Loved One With Cancer, with Paul S. Appelbaum, MD, Allison Magnuson, DO, and Jonathan M. Marron, MD, MPH
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In today’s podcast, Dr. Paul Appelbaum, Dr. Allison Magnuson, and Dr. Jonathan Marron, will discuss their article “Medical Decision-Making in Oncology for Patients Lacking Capacity,” from the 2020 ASCO Educational Book. They discus…
playlist_add
Oct 20, 2020
New Research in Genitourinary Cancers from ESMO Virtual Congress 2020, with Neeraj Agarwal, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Dr. Neeraj Agarwal discusses new research in kidney, prostate, and bladder cancer presented at the European Society for Medical Oncology Virtual Congress 2020. This meeting was held virtually September 19-21.
Dr. Ag…
playlist_add
Sep 3, 2020
ASCO20 Virtual Scientific Program Research Round Up: Central Nervous System Tumors and Lymphoma
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, attendees from 138 countries worldwide gathered virtua…
playlist_add
Aug 20, 2020
Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, PIVOT-09
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Aug 13, 2020
ASCO20 Virtual Scientific Program Research Round Up: Head and Neck Cancer and Melanoma
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, attendees from 138 countries worldwide gathered virtua…
playlist_add
Jul 27, 2020
Screening for Hepatitis B Virus Before Cancer Treatment, with Andrew Artz, MD, MS, and Jessica Hwang, MD, MPH
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Brielle Gregory: Hi, everyone. I'm Brielle Gregory, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clinica…
playlist_add
Jul 21, 2020
ASCO20 Virtual Scientific Program Research Round Up: Breast Cancer, Sarcoma, and Supportive Care
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, attendees from 138 countries worldwide gathered virtua…
playlist_add
Jul 14, 2020
Preventing and Managing Peripheral Neuropathy, with Charles Loprinzi, MD, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Brielle Gregory: Hi, everyone. I'm Brielle Gregory, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net Podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clinica…
playlist_add
Jul 9, 2020
Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, COSMIC-313
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Jun 23, 2020
ASCO20 Virtual Scientific Program Research Round Up: Leukemia, Colorectal Cancer, and Lung Cancer
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, a record 42,750 attendees from 138 countries worldwide…
playlist_add
Jun 18, 2020
Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto
ASCO: Usted está escuchando un pódcast de Cancer.Net en español. Este sitio web de información sobre el cáncer es producido por la Sociedad Estadounidense de Oncología Clínica, o la American Society of Clinical Oncology en inglés, la organización profesional líder en el mundo para médicos que atienden a personas con cáncer.
El propósito de este pódcast es instruir y brindar información. Esto no es un sustituto de la atención médica profesional y no está previsto que sea utilizado para el diagnóstico o el tratamiento de afecciones individuales. Los invitados de este pódcast expresan sus opiniones, experiencias y conclusiones. La mención de cualquier producto, servicio, organización, actividad o terapia no debe considerarse como aval por parte de la American Society of Clinical Oncology. La investigación sobre el cáncer que se analiza en este pódcast está en curso; por lo tanto, los datos descritos aquí pueden variar a medida que la investigación avanza.
Les…
playlist_add
May 20, 2020
Managing Cancer Cachexia, with Charles Loprinzi, MD, FASCO, and Hester Hill Schnipper, LICSW
[music]
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Greg Guthrie: Hi, everyone. I'm Greg Guthrie, a member of the cancer.net content team. And I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clin…
playlist_add
May 5, 2020
Clinical Trials in Genitourinary Cancers: KEYLYNK-010, KEYNOTE-866, PDIGREE
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Apr 1, 2020
Las evaluaciones geriátricas integrales, con Enrique Soto, MD
ASCO: Usted está escuchando un pódcast de Cancer.Net en español. Este sitio web de información sobre el cáncer es producido por la Sociedad Estadounidense de Oncología Clínica, o la American Society of Clinical Oncology en inglés, la organización profesional líder en el mundo para médicos que atienden a personas con cáncer.
El propósito de este pódcast es instruir y brindar información. Esto no es un sustituto de la atención médica profesional y no está previsto que sea utilizado para el diagnóstico o el tratamiento de afecciones individuales. Los invitados de este pódcast expresan sus opiniones, experiencias y conclusiones. La mención de cualquier producto, servicio, organización, actividad o terapia no debe considerarse como aval por parte de la American Society of Clinical Oncology. La investigación sobre el cáncer que se analiza en este pódcast está en curso; por lo tanto, los datos descritos aquí pueden variar a medida que la investigación avanza.
Les…
playlist_add
Feb 13, 2020
Clinical Trials in Genitourinary Cancers: VISION, INTACT, and PROSPER
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so clinical trials described here may no longer be enrolling patients, and final results are not yet available.
Before any new cancer treatment can be approved for general use, it must be studied in a clinical trial in order to prove it is safe and effective. In today’s podcast, members of th…
playlist_add
Jan 16, 2020
Lymphoma Highlights from the 2019 American Society of Hematology, with Michael E. Williams, MD, ScM
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams will discuss some of the new research in lymphoma that was presented at the 2019 American Society of Hematology Annual Meeting, held December seventh through tenth in…
playlist_add
Jan 9, 2020
Research Highlights from the 2019 San Antonio Breast Cancer Symposium, with Norah Lynn Henry, MD, PhD, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry discusses several studies presented at the 2019 San Antonio Breast Cancer Symposium, held December tenth through fourteenth in San Antonio, Texas. Dr. Henry is an Asso…
playlist_add
Dec 17, 2019
Coping With the Fear of Recurrence, with Hester Hill Schnipper, LICSW, OSW-C
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Greg Guthrie: Hi, everyone. I'm Greg Guthrie, a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Now as a reminder, Cancer.Net is the patient information website of ASCO, the American Socie…
playlist_add
Dec 5, 2019
Overcoming Barriers to Clinical Trial Enrollment, with Ryan D. Nipp, MD, MPH and Electra D. Paskett, PhD, MSPH
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In today’s podcast, Dr. Ryan Nipp and Dr. Electra Paskett will discuss their article “Overcoming Barriers to Clinical Trial Enrollment,” from the 2019 ASCO Educational Book. They discuss why it is important for people with canc…
playlist_add
Nov 14, 2019
Research Highlights from the European Society for Medical Oncology 2019 Congress, with Ricardo Cubedo, MD
[music]
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The European Society for Medical Oncology 2019 Congress was held in Barcelona, Spain, from September 27 to October 1. In this podcast, Dr. Ricardo Cubedo shares highlights from the meeting, including treatment advances in ov…
playlist_add
Oct 21, 2019
Research Highlights From the 2019 Supportive Care in Oncology Symposium, with William Dale, MD, PhD, and Joe Rotella, MD, MBA, HMDC, FAAHPM
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Greg Guthrie: Hi everyone, I'm Greg Guthrie, and I'm a member of the Cancer.Net content team. And I'll be your host for today's Cancer.Net podcast. As a reminder, Cancer.Net is the patient information website of ASCO, The American So…
playlist_add
Oct 17, 2019
New Research from the 2019 World Conference on Lung Cancer, with Vamsidhar Velcheti, MD, FACP, FCCP
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The 2019 World Conference on Lung Cancer was held September 7 to 10 in Barcelona, Spain. In this podcast, Dr. Vamsidhar Velcheti will discuss a study presented at this meeting that looked at the effects of a new drug targeting a spec…
playlist_add
Sep 3, 2019
Research Highlights from the ASCO Quality Care Symposium, with Merry Jennifer Markham, MD, FACP, and Neeraj Agarwal, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Monika Sharda: Hi, I'm Monica Sharda, an editor on the Cancer.Net team and your host for today's podcast. In this episode, we're going to discuss 2 studies on patient experiences with clinical trials that will be presented at ASCO's…
playlist_add
Aug 28, 2019
Food Anxiety and Cancer, with Julie Lanford, MPH, RD, CSO, LDN and Debra L. Benfield, MEd, RDN, LDN, RYT
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, registered dietitians Julie Lanford and Debra Benfield will discuss food anxiety before, during, and after cancer treatment, including potential causes and healthy ways to address food anxiety at any stage of treatme…
playlist_add
Aug 22, 2019
2019 ASCO Annual Meeting Research Round Up: Gastrointestinal Cancers and Leukemia
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The 2019 ASCO Annual Meeting, held May 31 to June 4, brought together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatmen…
playlist_add
Jul 25, 2019
Seguridad de los alimentos en verano, con Janice López-Muñoz, BS, MSIH y Clara Yuvienco, MPH
ASCO: Usted está escuchando un pódcast de Cancer.Net en español. Este sitio web de información sobre el cáncer es producido por la Sociedad Estadounidense de Oncología Clínica, o la American Society of Clinical Oncology en inglés, la organización profesional líder en el mundo para médicos que atienden a personas con cáncer.
El propósito de este pódcast es instruir y brindar información. Esto no es un sustituto de la atención médica profesional y no está previsto que sea utilizado para el diagnóstico o el tratamiento de afecciones individuales. Los invitados de este pódcast expresan sus opiniones, experiencias y conclusiones. La mención de cualquier producto, servicio, organización, actividad o terapia no debe considerarse como aval por parte de la American Society of Clinical Oncology. La investigación sobre el cáncer que se analiza en este pódcast está en curso; por lo tanto, los datos descritos aquí pueden variar a medida que la investigación avanza.
El…
playlist_add
Jul 18, 2019
2019 ASCO Annual Meeting Research Round Up: Soft-Tissue Sarcoma and Melanoma
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The 2019 ASCO Annual Meeting, held May 31 to June 4, brought together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatmen…
playlist_add
Jun 25, 2019
2019 ASCO Annual Meeting Research Round Up: Breast Cancer, Head and Neck Cancer, and Cancer-Related Nausea and Vomiting
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The 2019 ASCO Annual Meeting, held May 31 to June 4, brought together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatmen…
playlist_add
Jun 11, 2019
Leg Swelling After Cancer Treatment, with Andrea Cheville, MD, and Jennifer Bradt, PT, DPT, CLT-LANA
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, we’ll discuss lymphedema, or swelling, in the legs after cancer treatment, including what can cause lymphedema, and how to prevent and manage it. This podcast will be led by Dr. Andrea Cheville, the Director of Can…
playlist_add
Jun 2, 2019
Coming Soon: Research Round Up from the 2019 ASCO Annual Meeting
The 2019 ASCO Annual Meeting brings together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatment and patient care. In the annual Research Round Up podcast series from ASCO’s patient education website, Cancer.Net Associate Editors share their thoughts on the most exciting research in their areas of expertise and explain what it means for people living with cancer.
Look for the first Research Round Up podcast this June, and subscribe to Cancer.Net Podcasts on Apple Podcasts or Google Play for more expert podcasts for people with cancer.
playlist_add
Apr 9, 2019
Genetic Testing for Hereditary Breast and Ovarian Cancer, with Allison Kurian, MD, MSc
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Monika Sharda: Hi, I'm Monika Sharda, an editor at Cancer.Net, and your host for today's podcast. In this episode, we will discuss genetic testing for hereditary cancers. Our guest is Dr. Allison Kurian, a medical oncologist at Stanf…
playlist_add
Mar 5, 2019
Social Media for People With Cancer, with Merry Jennifer Markham, MD, and Danielle Gentile, PhD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Monika Sharda: Hello. I'm Monika Sharda, an editor on the Cancer.Net team and your host for today's podcast. In this episode, I will be talking with two guests about how cancer patients use social media. Our first guest, Dr. Merry Je…
playlist_add
Feb 19, 2019
Leukemia Highlights from the 2018 American Society of Hematology, with Guillermo Garcia-Manero, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Guillermo Garcia-Manero will discuss some of the new research in leukemia and myelodysplastic syndromes, or MDS, that was presented at the 2018 American Society of Hematology Annual Me…
playlist_add
Jan 29, 2019
Research Highlights from the 2018 San Antonio Breast Cancer Symposium, with Norah Lynn Henry, MD, PhD, FASCO
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry discusses new research that was presented at the 2018 San Antonio Breast Cancer Symposium, held December fourth through eight in San Antonio, Texas. Dr. Henry is an As…
playlist_add
Jan 22, 2019
Lymphoma Highlights from the 2018 American Society of Hematology, with Michael E. Williams, MD, ScM
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams will discuss some of the new research in lymphoma that was presented at the 2018 American Society of Hematology Annual Meeting, held December first through fourth in S…
playlist_add
Jan 8, 2019
Research Highlights in Kidney and Prostate Cancer from the European Society for Medical Oncology 2018 Congress, with Brian I. Rini, MD and Jorge A. Garcia, MD, FACP
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In this podcast, Cancer.Net Editorial Board members Dr. Brian Rini and Dr. Jorge Garcia discuss new research in kidney and prostate cancer presented at the European Society for Medical Oncology 2018 Congress, held October nineteenth…
playlist_add
Dec 6, 2018
ASCO In the Community in Sudbury, Massachusetts, with Colin D. Weekes, MD, PhD and the Reverend Joel B. Guillemette
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
ASCO President Dr. Monica Bertagnolli has chosen “Caring for every patient. Learning from every patient,” as her presidential theme. Putting actions to words, from 2018 to 2019, she is hosting a series of ASCO Presidential Commun…
playlist_add
Nov 2, 2018
Nutrition During and After Colorectal Cancer Treatment, with Suzanne Dixon, MPH, MS, RDN, and Julie Lanford, MPH, RD, CSO, LDN
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors that care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses.
In today's podcast, Suzanne Dixon and Julie Lanford discuss nutrition during and after treatment for colorectal cancer, including ways to manage side effects and guidelines for eating with a colostomy.
Suzanne Dixon is a registered dieti…
playlist_add
Oct 22, 2018
Telemedicine in Cancer Care, with Ana María López, MD, MPH, FACP, S. Joseph Sirintrapun, MD, FASCP, FCAP, Joseph A. Greer, PhD, and Karen E. Edison, MD
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
While most people may think of visiting a doctor to receive medical care, today, technology such as computers and smartphones can connect doctors and patients who are separated physically. This is known as “telemedicine.”
In tod…
playlist_add
Oct 9, 2018
Lifestyle Changes to Reduce the Risk of Cancer, with Noelle K. LoConte, MD, Jeffrey E. Gershenwald, MD, and Cynthia A. Thomson, PhD, RDN
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Many people are aware that quitting smoking or other tobacco use will reduce the risk that someone will develop cancer. In today’s podcast, Dr. Noelle LoConte, Dr. Jeffrey Gershenwald, and Dr. Cynthia Thomson will discuss their art…
playlist_add
Sep 20, 2018
Caring for a Spouse with Cancer, with Scott Joy
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Caring for a loved one with cancer can be challenging as well as rewarding. But you are not alone. In this series of podcasts, developed in collaboration with LIVESTRONG, Aditi Narayan and Mike Threadgould interview family caregivers…
playlist_add
Aug 27, 2018
Preserving Fertility for Young Women with Cancer, with Karen Lisa Smith, MD, MPH
You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
Many common cancer treatments can temporarily or permanently affect a woman’s fertility, which is the ability to have children. In today’s podcast, Dr. Karen Lisa Smith shares highlights from her article from the 2018 ASCO Educational…
playlist_add
Aug 22, 2018
2018 ASCO Annual Meeting Research Round Up: Childhood Cancers, Older Adults, Multiple Myeloma, and Lung Cancer
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
The ASCO Annual Meeting brings together physicians, researchers, patient advocates, and other health care professionals to discuss the latest in cancer care. The research presented at this meeting frequently leads to treatment advanc…
playlist_add
Aug 14, 2018
Improving Communication Between Patients and Health Care Providers, with Timothy Gilligan, MD, FASCO, and Liz Salmi
[music]
ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer.
The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses.
In today’s podcast, Dr. Timothy Gilligan and Liz Salmi will discuss their article “Patient-Clinician Communication Is a Joint Creation: Working Together Toward Well-Being,” from the 2018 ASCO Educational Book. They cov…
playlist_add
Aug 2, 2018
2018 ASCO Annual Meeting Research Round Up: Side Effects, Head and Neck Cancer, Breast Cancer, and Melanoma
The ASCO Annual Meeting brings together physicians, researchers, patient advocates, and other health care professionals to discuss the latest in cancer care. The research presented at this meeting frequently leads to treatment advances and new ways to improve the quality of life for people with cancer. In today’s podcast, Cancer.Net Associate Editors share their thoughts on the most exciting and practice-changing news to come out of the 2018 ASCO Annual Meeting.
playlist_add
Jul 19, 2018
Patient-Centered Care, with Meg Gaines, JD, LLM
This podcast features an interview with Martha "Meg" Gaines, Distinguished Clinical Professor of Law at the University of Wisconsin-Madison and Director of the Center for Patient Partnerships. She shares her personal experience with cancer and explains how it led her to advocate for others with cancer and found the Center for Patient Partnerships. She also discusses patient-centered care, and shares tips for patient advocates.
playlist_add
Jul 17, 2018
2018 ASCO Annual Meeting Research Round Up: Brain Tumors, Sarcomas, Pancreatic Cancer, Liver Cancer, and Kidney Cancer
The ASCO Annual Meeting brings together physicians, researchers, patient advocates, and other health care professionals to discuss the latest in cancer care. The research presented at this meeting frequently leads to treatment advances and new ways to improve the quality of life for people with cancer. In today’s podcast, Cancer.Net Associate Editors share their thoughts on the most exiting and practice-changing news to come out of the 2018 ASCO Annual Meeting.
playlist_add
May 21, 2018
Assessing and Managing Care for Older Adults, with Arti Hurria, MD, and William Dale, MD, PhD
Approximately 70% of people diagnosed with cancer are 65 or older, and often older adults with cancer have different needs and concerns than young adults or children. In this podcast, we will discuss new recommendations from ASCO about how doctors can assess older adults in order to ensure they get the care they need.
This podcast will be led by Dr. Arti Hurria and Dr. William Dale, two co-chairs of the expert panel that produced these recommendations.
playlist_add
May 8, 2018
How to Safely Handle and Dispose of Medications, with Paul Celano, MD
In this podcast, Dr. Paul Celano discusses what patients should know when taking medication for cancer treatment, including tips for safely storing the medication, special considerations for oral chemotherapy and opioids, as well as resources to help dispose of unneeded or expired medications.
playlist_add
Mar 5, 2018
Understanding Liquid Biopsy, with Nicholas Turner, MA, MRCP, PhD
In this podcast, Professor Nicholas Turner discusses liquid biopsy, which is a procedure that uses blood to test for cancer in the body.
playlist_add
Feb 28, 2018
Nutrition after Head and Neck Cancer Diagnosis, with Maureen Gardner, MA, RDN, CSO, and Annette M. Goldberg, MS, MBA, RDN, LDN
Treatment for head and neck cancer can often cause side effects that make it difficult to eat. In this podcast, dietitians Maureen Gardner and Annette Goldberg discuss several side effects that may be caused by head and neck cancer treatment and offer tips for managing these side effects and taking in enough nutrients, including information about feeding tubes.
playlist_add
Feb 16, 2018
Research Highlights from the 2018 Cancer Survivorship Symposium: Advancing Care and Research, with Timothy Gilligan, MD, FASCO
In this podcast, Dr. Timothy Gilligan will discuss new research presented at the 2018 Cancer Survivorship Symposium: Advancing Care and Research, held February 16-17 in Orlando, Florida. This multidisciplinary meeting brings together primary care physicians, oncologists, patient advocates, and others to discuss ways to address cancer survivors’ unique concerns.
The research discussed in this podcast includes mention of suicide. If you need help, contact the National Suicide Prevention Lifeline.
playlist_add
Feb 14, 2018
Understanding “Biosimilars,” with Gary H. Lyman, MD, MPH, FASCO, FRCP
Research into new forms of biologic therapy, such as immunotherapy or targeted therapy, have made dramatic advances in treating and managing cancer, but these therapies can be very expensive. You may be familiar with generic drugs, which are identical copies of brand-name drugs, and are often much cheaper. However, the manufacturing process for biologic therapies is so complex, it is not possible for a different manufacturer to make an identical copy.
In this podcast, Dr. Gary Lyman discusses biosimilar agents, which are similar, but not identical, copies of these drugs. Dr. Lyman discusses some of the differences in manufacturing biosimilar agents, the criteria that are used to ensure they are as effective as the original drug, and some of the ways that biosimilars can help reduce the cost of cancer care.
playlist_add
Nov 7, 2017
Alcohol and Cancer, with Noelle K. LoConte, MD
In today’s podcast, Dr. Noelle LoConte discusses the relationship between alcohol use and cancer, and explains why ASCO has released a statement on this topic.
Cancer Screening and Prevention
playlist_add
Oct 31, 2017
Physical Activity During and After Cancer Treatment, with Kristen Leung and Rachel Dudasik
There are many benefits to being physically active during and after cancer treatment. However, the side effects of cancer treatment can make it challenging to get to a gym or complete standard exercises. In this podcast, we discuss these challenges, tips for staying physically active, and the benefits of participating in a fitness program designed for cancer survivors, like LIVE*STRON*G at the YMCA.
After Treatment and Survivorship
playlist_add
Sep 26, 2017
Understanding the Ketogenic Diet, with Roy Strowd, MD, and Annette Goldberg, MS, MBA, RDN, LDN
A ketogenic diet is a high-fat, low-carbohydrate diet that has some specific neurological effects. In today’s podcast, Annette Goldberg talks with Dr. Roy Strowd about this diet, its history, and its potential benefits in people with certain types of brain tumors.
Cancer Research News
playlist_add
Sep 7, 2017
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment, with Ryan Nipp, MD, MPH
Many people with cancer receive long-term therapy after their primary cancer treatment—such as surgery or chemotherapy—has ended, in order reduce the risk of their cancer returning or worsening. In today’s podcast, Dr. Ryan Nipp discusses the unique challenges faced by people who receive this extended therapy and their caregivers. Dr. Nipp also talks about the importance of survivorship care plans and having open communication between patients and their health care team in addressing these challenges.
After Treatment and Survivorship
playlist_add
Aug 29, 2017
Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives, with Judith A. Paice, PhD, RN
In today’s podcast, Dr. Judith Paice discusses options for managing cancer-related pain, including opioid medications, and medication-free alternatives. She also discusses the use of cannabinoids, which are derived from marijuana, including recent clinical research and associated risks and barriers.
Side Effects
playlist_add
Aug 16, 2017
Improving Quality and Value of Cancer Care for Older Adults, with Erika E. Ramsdale, MD, and Andrew E. Chapman, DO, FACP
In today’s podcast, Dr. Erika Ramsdale and Dr. Andrew Chapman discuss new options for improving care for older adults with cancer, including online tools and telecommunications options. Dr. Ramsdale is a board-certified specialist in geriatric medicine and medical oncology at the University of Rochester Medical Center. Dr. Chapman is the co-director of the Jefferson Senior Adult Oncology Center and a board-certified medical oncologist and hematologist at Thomas Jefferson University.
Cancer Research News
playlist_add
Jun 29, 2017
Training a Pet as a Therapy Animal, with Leslie Horton
A therapy animal has been trained to visit hospitals and other healthcare environments to provide comfort, help decrease a patient’s pain or discomfort, encourage movement, and even serve a role in a patient’s treatment program. In today’s podcast, Leslie Horton will discuss what is involved in training a dog or other pet to become a therapy animal.
Family, Friends, and Caregivers
playlist_add
May 9, 2017
Genetic Counselors and Genetic Testing: Past, Present, and Future; with Tiffani DeMarco, MS, CGC
Genetic testing can help estimate a person’s chance of developing cancer in their lifetime based on changes, or mutations, in their genetic code. Genetic counselors are specially trained medical professionals who can assess and advise people on their individual risk of cancer based on their family’s history of cancer and the results of genetic testing. In this podcast, Tiffani DeMarco explains the role of a genetic counselor and discusses how genetic testing has changed over time.
Cancer Screening and Prevention
playlist_add
Apr 25, 2017
Voices on Cancer: Why Cancer in Young Adults Is Different, with Matthew Zachary
_Voices on Cancer_ is a Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. In this _Voices on Cancer_ podcast, young adult cancer survivor Matthew Zachary shares his advocacy story and shares tips to help advocate for young adults with cancer.
Cancer Basics
playlist_add
Apr 20, 2017
The Role of Art Therapists in Cancer Care, with Michelle Itczak
Through art therapy, someone with cancer can explore and express feelings that they may not be able to say aloud. In today’s podcast, Michelle Itczak will discuss the role of art therapy in cancer care, and what someone with cancer should know about working with an art therapist.
Cancer Basics
playlist_add
Mar 14, 2017
Quitting Smoking After a Cancer Diagnosis, with Anthony Alberg, PhD, MPH
In today’s podcast, Dr. Anthony Alberg explains why it’s not too late to quit smoking after a cancer diagnosis, including the immediate and long-term benefits during and after cancer treatment. He also addresses common myths around quitting smoking and provides resources for someone who wants to quit.
Cancer Research News
playlist_add
Feb 28, 2017
Accelerated Aging after Cancer Treatment, with Arti Hurria, MD, Lee Jones, PhD, and Hyman B. Muss, MD, FASCO
In today’s podcast, Dr. Arti Hurria, Dr. Lee Jones, and Dr. Hyman Muss will discuss their article “Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions.” They discuss research on why aging-related problems—such as physical conditions or cognitive decline—occur more frequently in cancer survivors, and how these aging-related problems can be prevented or minimized.
Cancer Research News
playlist_add
Dec 1, 2016
HPV and Cancer, with Howard Bailey, MD
In today’s podcast, Dr. Howard Bailey will discuss human papillomavirus, or HPV, and explain why it’s associated with certain types of cancer. He also discusses HPV vaccines, and how they can help lower the risk of these cancers.
Cancer Screening and Prevention
playlist_add
Nov 28, 2016
Using Technology to Improve Cancer Care, with Michael J. Fisch, MD, MPH, Melissa K. Accordino, MD, and Arlene E. Chung, MD, MHA, MMCi
In this podcast, Dr. Michael Fisch, Dr. Melissa Accordino, and Dr. Arlene Chung discuss their article, “Using Technology to Improve Cancer Care: Social Media, Wearables, and Electronic Health Records,” and explain how doctors are using digital technology to communicate with their patients, and each other.
Cancer Research News
playlist_add
Nov 22, 2016
The Role of an Oncology Advanced Practitioner, with Wendy Vogel, MSN, FNP, AOCNP
Cancer care has become increasingly complex, so someone with cancer will be treated by a collaborative team of health care providers that includes doctors, nurses, and a wide range of additional specialists. In today’s podcast, Wendy Vogel discusses the role of oncology advanced practitioners, or APs, as a part of this multidisciplinary team.
Cancer Basics
playlist_add
Nov 14, 2016
The Role of a Patient Navigator, with Lillie D. Shockney, RN, BS, MAS
In today’s podcast, Lillie Shockney discusses her article, “The Value of Patient Navigators as Members of the Multidisciplinary Oncology Care Team.” Nurse navigators, also known as patient navigators, help a person with cancer “navigate” the hospital and human services bureaucracies. This includes assisting with decision making, coordinating services, and advocating for the patient with the other members of the health care team.
Cancer Basics
playlist_add
Oct 27, 2016
Understanding Direct-to-Consumer Genetic Testing, with Nadine Tung, MD
In today’s podcast, we will discuss direct-to-consumer genetic testing. You may have seen these at-home genetic testing kits advertised on television or the internet. Genetic testing can be used to estimate a person's risk of developing specific diseases, such as cancer. However, direct-to-consumer genetic testing may have significant limitations, and the decision to be tested for cancer risk is complex. This podcast will be led by Dr. Nadine Tung, the Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center.
Cancer Screening and Prevention
playlist_add
Oct 17, 2016
Understanding Electronic Patient-Reported Outcomes, with Lee Schwartzberg, MD, FACP
Patient-reported outcomes, or PROs, are anything reported directly by the patient, such as symptoms or emotions. In today’s podcast, Dr. Lee Schwartzberg discusses his article, “Electronic Patient-Reported Outcomes: The Time Is Ripe for Integration Into Patient Care and Clinical Research,” and explains how electronic PRO systems can help improve communication between patients and their health care team.
Cancer Research News
playlist_add
Oct 6, 2016
Fasting and Cancer, with Suzanne Dixon, MPH, MS, RDN and Annette Goldberg, MS, MBA, RDN, LDN
To fast is to partially or completely reduce one’s food intake for a period of time. In today’s podcast, Suzanne Dixon and Annette Goldberg discuss the history of fasting, different types of diets, and why some scientists are researching the effects of fasting during or after cancer treatment. They also provide tips for someone considering fasting during treatment.
Quality of Life
playlist_add
Aug 8, 2016
Chemotherapy before Surgery for Advanced Ovarian Cancer, with Alexi A. Wright, MD, and Mitchell I. Edelson, MD
In today’s podcast, we will discuss new recommendations developed jointly by ASCO and the Society for Gyncologic Oncology on when women with newly diagnosed, advanced ovarian cancer should receive neoadjuvant chemotherapy, which is chemotherapy given before surgery. These recommendations are intended to help guide doctors and their patients in making treatment decisions based on current research.
Cancer Research News
playlist_add
Jul 19, 2016
Introduction to the TAPUR Study, with Richard Schilsky, MD, FACP, FASCO
In today’s podcast, ASCO’s Chief Medical Officer, Dr. Richard Schilsky, discusses ASCO’s first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry, or TAPUR Study. The TAPUR Study is a clinical trial for people with later-stage cancer, focused on whether specific targeted therapies can benefit more patients and lead to more personalized treatments. Dr. Schilsky explains the objectives of the study, and provides information about who might be eligible to participate, as well as what is involved.
Cancer Research News
playlist_add
Jun 16, 2016
Nutrition Myths, with Suzanne Dixon, MPH, MS, RDN and Annette Goldberg, MS, MBA, RDN, LDN
n today’s podcast, Suzanne Dixon and Annette Goldberg discuss and dispel several common myths about nutrition and cancer. Suzanne Dixon is a Registered Dietitian and Epidemiologist, with a nutrition and research consulting business in Portland, Oregon. Annette Goldberg is an Outpatient Dietitian at the Boston Medical Center Cancer Care Center.
Cancer Basics
playlist_add
May 24, 2016
Surgery for Older Adults with Cancer, with Beatriz Korc-Grodzicki, MD, PhD
Over 60% of people who have cancer are 65 or older. In today’s podcast, we will discuss some of the unique challenges older adults with cancer may face, including special considerations for preparing for and recovering from surgery.
Quality of Life
playlist_add
May 3, 2016
Getting a Better Night's Sleep, with Peggy S. Burhenn, MS, CNS, AOCNS
In today’s podcast, Peggy Burhenn, a nurse and professional practice leader in Geriatric Oncology at City of Hope National Medical Center discusses several strategies for getting a better night’s sleep.
Quality of Life
playlist_add
Apr 21, 2016
Understanding Prehabilitation, with Arash Asher, MD, and An Ngo-Huang, DO
In today’s podcast, Cancer.Net Advisory Panelist Dr. Arash Asher talks to Dr. An Ngo-Huang about prehabilitation and why it is becoming a more common element of cancer treatment.
Quality of Life
playlist_add
Mar 17, 2016
Understanding the Importance of Psychosocial Cancer Care, with Peter Brown and Victoria Sardi-Brown, PhD
In today’s podcast, Mattie Miracle Cancer Foundation co-founders Peter Brown and Vicki Sardi-Brown tell the story of their son Mattie’s journey with cancer, and explain how it inspired them to advocate for the development of evidence-based psychosocial standards of care for children with cancer and their families.
Family, Friends, and Caregivers
playlist_add
Mar 8, 2016
Understanding Palliative Care, with Kavitha Ramchandran, MD
Palliative care focuses on preventing, managing, and relieving the symptoms of cancer and the side effects of cancer treatment. In this podcast, Dr. Kavitha Ramchandran discusses the basics of palliative care, including when a person with cancer should consider palliative care and the role of a multidisciplinary palliative care team.
Quality of Life
playlist_add
Feb 16, 2016
The Role of Oncology Dietitians in Cancer Care, with Maureen Gardner, MA, RDN, CSO, and Annette M. Goldberg, MS, MBA, RDN, LDN
Some side effects of cancer treatment—such as taste changes and appetite loss—can prevent a person receiving cancer treatment from eating and drinking enough. In this podcast, oncology dietitians Maureen Gardner and Annette Goldberg will discuss how they work with people with cancer and their families to address these and other common nutrition concerns.
Cancer Basics
playlist_add
Dec 1, 2015
2015 ASCO Educational Book - Treating Older Adults with Cancer, with Heidi D. Klepin, MD, MS, Miriam Rodin, MD, PhD, and Arti Hurria, MD
In this podcast, Dr. Heidi Klepin, Dr. Miriam Rodin, and Dr. Arti Hurria, will discuss their 2015 ASCO Educational Book article “Treating Older Adults with Cancer: Geriatric Perspectives,” which explores some of the unique concerns that should be considered when older adults are being treated for cancer.
Cancer Research News
playlist_add
Nov 10, 2015
2015 ASCO Educational Book - Using Social Media to Learn and Communicate about Cancer, with Michael A. Thompson, MD, PhD and Nathan A. Pennell, MD, PhD
In this podcast, Dr. Michael Thompson discusses his article, “Using Social Media to Learn and Communicate: It Is Not About the Tweet” with Dr. Nathan Pennell.
Cancer Research News
playlist_add
Oct 13, 2015
2015 ASCO Educational Book - Screening for Lung Cancer, with Bernardo H.L. Goulart, MD, MS
In this podcast, Dr. Bernardo Goulart discusses his article, "The Value of Lung Cancer CT Screening."
Cancer Research News
playlist_add
Sep 22, 2015
2015 ASCO Educational Book - The Future of Cancer Treatment with Molecular Medicine, with Edward S. Kim, MD, FACP
In this podcast, Dr. Edward Kim discusses his article, “The Future of Molecular Medicine: Biomarkers, BATTLEs, and Big Data.”
Cancer Research News
playlist_add
Sep 8, 2015
2015 ASCO Educational Book - Sexual Healing in Patients with Prostate Cancer on Hormone Therapy, with Leslie R. Schover, PhD
In today’s podcast, Dr. Leslie Schover discusses her article, “Sexual Healing in Patients with Prostate Cancer on Hormone Therapy," from the 2015 ASCO Educational Book.
Cancer Research News
playlist_add
Jun 4, 2015
Just Diagnosed with Metastatic Bladder Cancer--Now What? with Charles Ryan, MD, and Thomas Powles, MBBS, MRCP, MD
This podcast is part of a series for patients who have just been diagnosed with a specific genitourinary, or GU cancer. In this series, Dr. Charles Ryan, a medical oncologist and professor who specializes in the genitourinary tract at the UCSF Helen Diller Family Comprehensive Cancer Center, speaks with experts on specific GU cancers to shed light on what happens after an initial diagnosis.
Today’s guest is Dr. Thomas Powles, clinical professor of genitourinary oncology at Barts Cancer Institute in London. In this podcast, Dr. Ryan and Dr. Powles discuss what happens after a diagnosis of metastatic bladder cancer, including new advances in immunotherapy for bladder cancer.
Cancer Basics
playlist_add
May 5, 2015
Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer, with Andreas Rimner, MD and John Robert Strawn, MD
In this podcast, we will discuss new recommendations for radiation therapy to treat locally advanced non-small cell lung cancer, developed by the American Society for Radiation Oncology and endorsed by ASCO.
Cancer Research News
playlist_add
Apr 14, 2015
Just Diagnosed with Kidney Cancer--Now What? with Charles Ryan, MD and Brian Rini, MD
This podcast is part of a series for patients who have just been diagnosed with a specific genitourinary, or GU cancer. In this series, Dr. Charles Ryan, a medical oncologist and associate professor who specializes in the genitourinary tract at the UCSF Helen Diller Family Comprehensive Cancer Center, speaks with experts on specific GU cancers to shed light on what happens after an initial diagnosis.
Today’s guest is Dr. Brian Rini, an associate professor of medicine and a staff member in the Department of Solid Tumor Oncology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Ryan and Dr. Rini discuss the decisions that doctors make when a patient is diagnosed with kidney cancer, including some of the factors that go into recommending certain treatment options.
Cancer Basics
playlist_add
Mar 17, 2015
The Role of Pathologists in Cancer Care, with Carey August, MD and Chanjuan Shi, MD, PhD
In this podcast, we’ll discuss the role of pathologists in cancer care.
Cancer Basics
playlist_add
Mar 5, 2015
Living with Lymphedema, with Judith Nudelman, MD
Today’s podcast is about living with lymphedema, a build-up of fluid that may occur after cancer treatment. This podcast will be led by Dr. Judith Nudelman, a family physician and certified lymphedema therapist.
Side Effects
playlist_add
Jan 22, 2015
The Role of Marriage and Family Therapists in Cancer Care, with June C. Foss, LMFT and Cheyenne Corbett, PhD, LMFT
A diagnosis of cancer can bring up many emotions and cause stress, anxiety, or depression for both patients and their families. In this podcast, we’ll discuss how seeing a Licensed Marriage and Family Therapist can help a person with cancer, how to find a marriage and family therapist, and what to expect from your visits.
Cancer Basics
playlist_add
Dec 15, 2014
Phase I Clinical Trials, with Jeffrey S. Weber, MD, PhD
In this podcast, we’ll discuss phase I clinical trials.
Treatments, Tests, and Procedures
playlist_add
Dec 2, 2014
“Scan-xiety,” with Lidia Schapira, MD
In this podcast, Dr. Lidia Schapira discusses ways to cope with feeling anxious about having scans for cancer and waiting for the results*.*
Treatments, Tests, and Procedures
playlist_add
Nov 18, 2014
The Role of a Medical Interpreter in Cancer Care, with Debra Haynes, MPH, Alejandro Muzio, George Donald, and Mariano Siles
In this podcast, Debra Haynes talks with Alejandro Muzio, George Donald, and Mariano Siles about meeting and working with a medical interpreter.
Cancer Basics
playlist_add
Nov 3, 2014
Radiation Therapy After Surgery for Prostate Cancer, with Howard Sandler, MD, MS
In this podcast, Dr. Howard Sandler discusses recommendations endorsed by ASCO for radiation therapy after prostatectomy, which is the removal of a man’s prostate.
Treatments, Tests, and Procedures
playlist_add
Oct 30, 2014
CT Scans and Cancer Risk, with Rebecca Smith-Bindman, MD
In this podcast, Dr. Rebecca Smith-Bindman explains the cancer risks associated with computed tomography, _or CT_, scans and the importance of discussing the risks and benefits of this imaging test with your doctor*.*
Treatments, Tests, and Procedures
playlist_add
Oct 16, 2014
The Role of a Child Life Specialist in Cancer Care, with Carolyn Fung, CCLS and Molly Spragins, CCLS
In this podcast, we’ll discuss meeting and working with a Child Life Specialist and some of the techniques they teach children to help them cope with their diagnosis and treatment.
Cancer Basics
playlist_add
Sep 23, 2014
The Role of a Physical Therapist in Cancer Care, with Sharlynn Tuohy, PT, DPT, MBA and Jean Kotkiewicz, PT, DPT, CLT
Many people are familiar with physical therapists, or PTs, for sports injuries or for issues with muscles, joints, and bones, but PTs can treat a variety of functional problems. In this podcast, we discuss how seeing a PT can help a person with cancer, including how to know if you should visit a PT and what to expect during your visits.
Quality of Life
playlist_add
May 8, 2014
The Role of an Oncology Nurse, with Mary Gullatte, PhD, RN, ANP, BC, AOCN®, FAAN and Cynthia Cantril, RN
In this podcast, we discuss the role of an oncology nurse.
Quality of Life
playlist_add
Apr 10, 2014
The Role of Oncology Social Workers, with Iris Cohen Fineberg, PhD, MSW, and Penelope Damaskos, PhD
Iris Cohen Fineberg, PhD, MSW, ACSW, OSW-C, and Penelope Damaskos, PhD, LCSW, OSW-C, discuss how social workers help patients get holistic care in partnership with the rest of the health care team.
Cancer Basics
playlist_add
Mar 4, 2014
Understanding the Costs Related to Cancer Care
Common costs related to cancer care.
Quality of Life
playlist_add
Feb 10, 2014
What Are Clinical Trials?
This podcast explains what clinical trials are, and how they are conducted.
Cancer Basics
playlist_add
Jan 6, 2014
Choosing a Doctor for Your Cancer Care
In this podcast, we discuss how to choose a doctor for your cancer care.
Cancer Basics
playlist_add
Nov 12, 2013
Biopsy - What to Expect
In this podcast, we discuss what you can expect if you are scheduled for a biopsy.
Cancer Screening and Prevention
playlist_add
Sep 20, 2013
The Role of Physician Assistants in Cancer Care, with Heather Hylton, MD, PA-C, and Todd Pickard, MMSc, PA-C
In this podcast, we discuss the role of Physician Assistants in cancer care. This podcast will be led by Heather Hylton and Todd Pickard.
Quality of Life
playlist_add
Apr 22, 2013
The Role on an Oncology Pharmacist, with R. Donald Harvey, PharmD, FCCP, BCOP and John Valgus, PharmD, BCOP, CPP
In this podcast, we discuss the role of an oncology pharmacist. This podcast is led by Drs. R. Donald Harvey and John Valgus.
Quality of Life
playlist_add
Mar 18, 2013
Colonoscopy - What to Expect
During this podcast, you'll receive some key facts about colonoscopy and an explanation of what happens during this test, to help you prepare for your own colonoscopy. You will also be offered a list of questions to ask your doctor about your test and its results.
Treatments, Tests, and Procedures
playlist_add
Jan 14, 2013
Understanding ASCO’s Recommendations for Managing Febrile Neutropenia, with Christopher Flowers, MD
In this podcast, we discuss ASCO’s recommendations for managing a symptom of cancer and cancer treatment called febrile neutropenia_._ This podcast is led by Dr. Christopher Flowers, who is an associate professor at the Winship Cancer Institute in the Department of Hematology/Oncology at Emory University in Atlanta.
Treatments, Tests, and Procedures
playlist_add
Oct 22, 2012
Mammography - What to Expect
This podcast explains what to expect during a mammogram.
Treatments, Tests, and Procedures
playlist_add
Sep 24, 2012
Pap Test - What to Expect
This podcast explains what to expect during a Pap test, or Pap smear.
Treatments, Tests, and Procedures
playlist_add
Mar 26, 2012
Coping With the Fear of Side Effects
How to cope with the fear of side effects before starting cancer treatment.
Side Effects
playlist_add
Mar 19, 2012
Making Decisions About Cancer Treatment
In this podcast, we talk about some practical steps that may help you make important decisions about your cancer treatment.
Cancer Basics
playlist_add
Feb 27, 2012
Just for Teens - Cancer and School
How teenagers with cancer can balance school and treatment.
Quality of Life
playlist_add
Oct 31, 2011
When the Doctor Says Cancer
In this podcast, we talk about the first steps to take when you are diagnosed with cancer.
Cancer Basics
playlist_add
Feb 17, 2010
Dental Health During Cancer Treatment
In this podcast, we'll talk about the types of cancer treatments that may cause oral side effects, as well as the ways people with cancer can prevent and manage such dental problems.
Side Effects
playlist_add
Sep 9, 2009
Barium Enema - What to Expect
In this podcast, we'll explain what happens during a barium enema and how you can prepare for the procedure, including a list of questions to ask your doctor.
Treatments, Tests, and Procedures
playlist_add
Jul 1, 2009
The Importance of Hydration
In this podcast, we'll review why people with cancer have a higher risk of dehydration, what symptoms to watch out for that may signal dehydration, and offer five simple ways to help keep your body's fluid supply in balance.
Quality of Life
playlist_add